CN111393476B - Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof - Google Patents

Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof Download PDF

Info

Publication number
CN111393476B
CN111393476B CN202010223130.7A CN202010223130A CN111393476B CN 111393476 B CN111393476 B CN 111393476B CN 202010223130 A CN202010223130 A CN 202010223130A CN 111393476 B CN111393476 B CN 111393476B
Authority
CN
China
Prior art keywords
formula
reaction
phos
rong
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010223130.7A
Other languages
Chinese (zh)
Other versions
CN111393476A (en
Inventor
张俊良
张荣华
徐杉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Kaitailai Platinum Technology Co ltd
Original Assignee
East China Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China Normal University filed Critical East China Normal University
Priority to CN202010223130.7A priority Critical patent/CN111393476B/en
Publication of CN111393476A publication Critical patent/CN111393476A/en
Application granted granted Critical
Publication of CN111393476B publication Critical patent/CN111393476B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/50Organo-phosphines
    • C07F9/5022Aromatic phosphines (P-C aromatic linkage)
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • B01J31/2282Unsaturated compounds used as ligands
    • B01J31/2295Cyclic compounds, e.g. cyclopentadienyls
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/2672-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • C07D211/76Oxygen atoms attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • C07D223/10Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0033Iridium compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60Reduction reactions, e.g. hydrogenation
    • B01J2231/64Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0225Complexes comprising pentahapto-cyclopentadienyl analogues
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0238Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0261Complexes comprising ligands with non-tetrahedral chirality
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/827Iridium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a new type (1) chiral bidentate nitrogen phosphine ligand Rong-Phos and a preparation method and application thereof. The invention also discloses a chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex shown in the formula (2) and a nitrogen chiral center high enantioselectivity construction method and application thereof. The iridium complex has both a carbon chiral center and a nitrogen chiral center and is stable in property, the method for constructing the nitrogen atom center of the iridium complex with high enantioselectivity is adopted, a pair of diastereomer catalysts with different nitrogen center chiralities of the iridium complex is applied to asymmetric hydrogenation reaction of cyclic unsaturated carbonyl compounds, and the iridium complex obtains excellent reaction activity and enantioselectivity in asymmetric hydrogenation reaction of other cyclic unsaturated carbonyl compounds, is remarkably excellent in effect, and has scientific research value and wide application prospect.

Description

Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof
Technical Field
The invention belongs to the technical field of organic chemistry, and particularly relates to a novel chiral bidentate nitrogen phosphine ligand, and preparation and application thereof.
Background
Chirality widely exists in nature, chiral compounds cannot be overlapped with each other just like the left hand and the right hand of people, and two enantiomers are mirror images of each other but cannot be completely overlapped. Two enantiomers that appear to be close, however, often have different optical, physicochemical, and biological activities that are different or even diametrically opposed.
In 2001, the Nobel prize was awarded to Knowles, Noyori and Sharpless for asymmetric catalytic hydrogenation and asymmetric catalytic oxidation studies. Asymmetric hydrogenation is one of the most effective methods for preparing various optically pure compounds because of its high efficiency, atom economy and good industrial application prospects. In particular, a large amount of studies have been made on the preparation of chiral amines, chiral amino acids, chiral alcohols, chiral carboxylic acids, etc., and have been successfully applied industrially. The chiral compounds have important and wide application value, and the asymmetric preparation of the chiral compounds is always a research focus and a hot spot in the field of organic synthesis. Among them, asymmetric catalysis, especially asymmetric hydrogenation, is gradually showing great potential in its industrial production due to its advantages of high efficiency, greenness and economy.
Chiral phosphine Ligands such as SIPHOX are widely used in asymmetric catalytic hydrogenation (C.C.Bausch, A.Pfaltz, Privileged Chiral Ligands and Catalysts (Ed.: Q. -L.Zhou), Wiley-VCH, Weinheim,2011, Chap.6, pp.221-256), such Ligands are used in asymmetric catalytic hydrogenationChiral phosphine nitride, and transition metal complexes can be used as asymmetric catalytic hydrogenation catalyst. The chiral centers commonly used in chiral ligands are carbon, phosphorus, and sulfur chiral centers because they are stable and when sp is3When a hybridized nitrogen atom connects three different groups, the nitrogen atom can also become a chiral center, but the chirality of the nitrogen atom is easy to flip and is unstable, so that the chirality of the nitrogen atom is generally not considered, and therefore the nitrogen atom is not used as the chiral center to design a corresponding chiral ligand. Although some chiral ligands containing nitrogen have been reported, the effect and effect of chirality at the nitrogen center in asymmetric catalytic reactions has not been investigated. We hypothesized whether stable chirality of nitrogen centers can be constructed when a nitrogen atom is coordinated to a metal based on kinetic and thermodynamic stability, to obtain stable metal complexes with nitrogen chiral centers and use them in asymmetric catalytic reactions. This scientific problem opportunity, together with the challenge, deserves our exploration. The subject group has been working on the development of novel C-centered chiral monophosphine ligands (catalysts), leading to the development of Ming-Phos (angelw.chem.int.ed.2014, 53,4350; angelw.chem., int.ed.2016,55,6324; acscataal.2015, 5,7488; acscataal.2017, 7,210), Xiao-Phos (angelw.chem.int.ed.2015, 54,6874), Wei-Phos (angel.chem.int.ed.2015, 54,14853), Peng-Phos (angelw.chem.int.ed.2016, 55,13316), PC-Phos (angelw.chem.chem., int.2017, 56,15905; j.am.chem.soc.2018,140,3467) and N-Phos (angels.chem.2018, 140,3467) and a number of these highly efficient monophosphine ligands (catalysts, many asymmetric catalysts, many of which are available.
Disclosure of Invention
The invention aims to provide a novel chiral bidentate nitrogen phosphine ligand Rong-Phos and a preparation method thereof, a Rong-Phos iridium complex nitrogen chiral center high enantioselectivity preparation method and application thereof in asymmetric catalytic hydrogenation.
The invention provides and synthesizes a new chiral bidentate nitrogen phosphine ligand Rong-Phos, and the ligand has a simple structure, a simple preparation method, a plurality of modifiable sites and a wide application prospect. It is worth mentioning that the Rong-Phos provided by the invention can construct an iridium complex with carbon center chirality and nitrogen center chirality at the same time with high enantioselectivity when being coordinated with transition metal iridium, and the characteristic endows the iridium complex with different activities and different chiral environments in a catalytic process, which cannot be realized by other ligands. The iridium complex contains four isomers in total, and iridium complexes with different stereo structures have different properties and advantages. The invention can accurately control the construction of carbon center chirality and nitrogen center chirality with high enantioselectivity, and applies the iridium complexes to asymmetric catalytic hydrogenation reaction of cyclic unsaturated carbonyl compounds. The iridium complex has only difference of chirality of nitrogen center, but different chiral environments in the catalysis process, products with R configuration and S configuration can be obtained with high enantioselectivity respectively, the iridium complex becomes a successful case for solving the chemical problem of synthesizing a pair of enantiomers by using a ligand with one configuration, and the iridium complex also shows excellent reaction activity and high enantioselectivity in the asymmetric hydrogenation reaction of other cyclic unsaturated carbonyl compounds, and has scientific research value and wide application prospect.
The novel chiral bidentate nitrogen phosphine ligand Rong-Phos and the ionic iridium complex thereof have four configurations because the iridium complex has carbon center chirality and nitrogen center chirality at the same time, and can obtain four optically pure ionic iridium complexes with full configurations at high enantioselectivity.
The chiral bidentate nitrogen phosphine ligand Rong-Phos and the chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex respectively have structural formulas shown as the following formulas (1) and (2):
Figure BDA0002426768050000021
in the above (formula 1) or (formula 2): ar is selected from
Figure BDA0002426768050000022
R1Selected from hydrogen, C1~C12Alkyl of (A), C1~C12Alkoxy group of,
Figure BDA0002426768050000031
Figure BDA0002426768050000032
R2、R3Are respectively and independently selected from hydrogen and C1~C12Alkyl of (A), C1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of,
Figure BDA0002426768050000033
ORw、SRw;R4、R5Are respectively and independently selected from hydrogen and C1~C12An alkyl group of,
Figure BDA0002426768050000034
Wherein R isxAnd Rx’Are respectively and independently selected from hydrogen, halogen and C1~C12Alkyl of (A), C1~C10Alkoxy group of (C)1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of (a); ry、RzAnd RwAre each independently selected from C1~C12Alkyl of (A), C1~C10Alkoxy group of (C)1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of (a); n is an integer of 1-5;
x is: BARF-、BF4 -、PF6 -Or Cl-An anion of any of (1).
Preferably, Ar in the above (formula 1) or (formula 2) is selected from
Figure BDA0002426768050000035
Figure BDA0002426768050000036
R1Is selected from C1~C12An alkyl group of,
Figure BDA0002426768050000037
R2、R3Are respectively and independently selected from hydrogen and C1~C12Alkyl of (A), C1~C10Siloxane group of (A), C1~C10An ester group of,
Figure BDA0002426768050000038
R4、R5Are respectively and independently selected from hydrogen and C1~C12An alkyl group of,
Figure BDA0002426768050000039
Wherein R isxAnd Rx’Are respectively and independently selected from hydrogen, halogen and C1~C12Alkyl of (A), C1~C10Alkoxy group of (C)1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of (a); n is an integer of 1 to 5.
Further preferably, Ar in the formula (1) or the formula (2) is selected from the group consisting of
Figure BDA0002426768050000041
Figure BDA0002426768050000042
R1Is selected from C1~C12An alkyl group of,
Figure BDA0002426768050000043
R2、R3Are respectively and independently selected from hydrogen and C1~C12An alkyl group of,
Figure BDA0002426768050000044
R4、R5Are respectively and independently selected from hydrogen and C1~C12An alkyl group of,
Figure BDA0002426768050000045
Wherein R isxAnd Rx’Are respectively and independently selected from hydrogen, halogen and C1~C12And n is an integer of 1 to 5.
In the invention, the compound of the formula (1) is purified by a silica gel column to obtain an optically pure compound shown as a formula (S) -1 and (R) -1;
Figure BDA0002426768050000046
in the formula:
ar is selected from
Figure BDA0002426768050000047
R1Selected from hydrogen, C1~C12Alkyl of (A), C1~C12Alkoxy group of,
Figure BDA0002426768050000048
Figure BDA0002426768050000049
R2、R3Are respectively and independently selected from hydrogen and C1~C12Alkyl of (A), C1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of,
Figure BDA0002426768050000051
ORw、SRw
R4、R5Are respectively and independently selected from hydrogen and C1~C12An alkyl group of,
Figure BDA0002426768050000052
Wherein R isxAnd Rx’Are respectively and independently selected from hydrogen, halogen and C1~C12Alkyl of (A), C1~C10Alkoxy group of (C)1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of (a);
Ry、Rzand RwAre each independently selected from C1~C12Alkyl of (A), C1~C10Alkoxy group of (C)1~C10Siloxane group of (A), C1~C10Alkanoyl of (2), C1~C10Ester group of (1), C1~C10A sulfonate group of (a);
n is an integer of 1 to 5.
As a still further preferred embodiment, the chiral bidentate azaphosphine ligand Rong-Phos and Rong-Phos iridium complex is selected from the group consisting of the following compounds;
Figure BDA0002426768050000053
Figure BDA0002426768050000061
wherein: ph is phenyl, Ad is 1-adamantyl, Me is methyl, Bn is benzyl, and nBu is n-butyl.
The invention discloses a chiral bidentate nitrogen phosphine ligand Rong-Phos and a high enantioselectivity preparation method of an ionic iridium complex thereof.
The invention provides a synthesis method of a chiral bidentate nitrogen phosphine ligand Rong-Phos, which comprises the following three steps.
The method comprises the following steps: comprises the following first step and second step;
reference is made to the patent granted to this subject group-chiral sulfinamide monophosphine ligand, its full configuration preparation method and application (application number: CN201310671902.3, publication number: CN103709195A) to prepare the chiral sulfinamide monophosphine ligand Ming-Phos described in the present invention, i.e., the compound of formula (3). Then, a nitrogen atom substituted Ming-Phos, namely the compound shown as the formula (4), is generated through a substitution reaction, and then, a hydrolysis reaction is carried out under the action of hydrochloric acid to obtain the chiral bidentate nitrogen phosphine ligand Rong-Phos.
The first step is as follows: starting from a compound of the following formula (3), under the action of a base, and reacting with R4Carrying out substitution reaction on the X to obtain a nitrogen atom substituted Ming-Phos compound;
wherein the compound of formula (3) comprises formula (S)C,RS) -3, formula (S)C,SS) -3, formula (R)C,SS) -3, formula (R)C,RS)-3;
Wherein the nitrogen atom substituted Ming-Phos compound comprises the formula (S)C,RS) -4, formula (S)C,SS) -4, formula (R)C,SS) -4, formula (R)C,RS)-4;
Wherein the base comprises BuLi, NaH, K2CO3,Na2CO3,KHCO3,NaHCO3,KOH,NaOH;
The reaction scheme of the first step is as follows:
Figure BDA0002426768050000071
wherein, the compound of formula (3), a base and R4The molar ratio of X is 1: 0.1-10; the reaction temperature is-78-30 ℃; the reaction time is 0.5 to 12 hours. The solvent may be dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene,One or any mixture of xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane. The alkali is used for exchanging with halogen X and carrying out substitution reaction in the reaction; the alkali comprises BuLi, NaH, K2CO3,Na2CO3,KHCO3,NaHCO3,KOH,NaOH。
The second step is that: the compound of formula (S)C,RS) -4, formula (S)C,SS) -4, formula (R)C,SS) -4, formula (R)C,RS) -4, under the action of hydrochloric acid, carrying out hydrolysis reaction to obtain chiral bidentate phosphine nitride Rong-Phos formula (S) -1 and formula (R) -1;
the reaction formula of the second step is as follows:
Figure BDA0002426768050000081
wherein the molar ratio of the compound shown in the formula (4) to HCl is 1: 0.1-10; the reaction temperature is 0-30 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one or any mixture of methanol, ethanol, n-butanol, isopropanol, dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane.
The invention also provides another method for preparing the chiral bidentate nitrogen phosphine ligand Rong-Phos, which comprises the following steps:
and in the second method, the Ming-Phos, namely the compound shown as the formula (3), is subjected to hydrolysis reaction under the action of hydrochloric acid to obtain intermediates shown as the formula (A) and the formula (B), and the intermediates are subjected to condensation and reduction with aldehyde without purification to obtain the chiral bidentate nitrogen phosphine ligand Rong-Phos.
Figure BDA0002426768050000082
The first step is as follows: starting from the compound of formula (3), under the action of hydrochloric acid, hydrolysis reaction occursObtaining intermediates shown in formula (A) and formula (B): wherein the compound of formula (3) comprises formula (S)C,RS) -3, formula (S)C,SS) -3, formula (R)C,SS) -3, formula (R)C,RS)-3;
The reaction scheme of the first step is as follows:
Figure BDA0002426768050000091
wherein the molar ratio of the compound shown in the formula (3) to HCl is 1: 0.1-10; the reaction temperature is 0-30 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one or any mixture of methanol, ethanol, n-butanol, isopropanol, dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane.
The second step is that: the intermediate shown in the formula (A) and the formula (B) is subjected to condensation with aldehyde and reduction by a reducing agent to obtain chiral bidentate phosphine nitride Rong-Phos formula (S) -1 and formula (R) -1;
the reaction formula of the second step is as follows:
Figure BDA0002426768050000101
wherein, the intermediate
Figure BDA0002426768050000102
The molar ratio of the aldehyde to the reducing agent is 1: 0.1-10; the reaction temperature is 0-30 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one of methanol, ethanol, n-butanol, isopropanol, dichloromethane, 1, 2-dichloroethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform, n-hexane or any mixture thereof. The reducing agentIncluding sodium borohydride, sodium triacetoxyborohydride, borane, lithium aluminum hydride, sodium hydride, DIBAL, potassium borohydride.
The invention also provides another method for preparing the chiral bidentate nitrogen phosphine ligand Rong-Phos, which comprises the following steps:
and in the third method, starting from Ming-Phos, namely the compound shown in the formula (3), in the second method, hydrolysis reaction is carried out under the action of hydrochloric acid to obtain an intermediate, and the intermediate is subjected to substitution reaction with alkyl halide without purification to obtain the chiral bidentate nitrogen phosphine ligand Rong-Phos.
Figure BDA0002426768050000103
The first step is as follows: starting from a compound shown in the following formula (3), carrying out hydrolysis reaction under the action of hydrochloric acid to obtain an intermediate shown in the formula (A) and the formula (B); wherein the compound of formula (3) comprises formula (S)C,RS) -3, formula (S)C,SS) -3, formula (R)C,SS) -3, formula (R)C,RS)-3;
The reaction scheme of the first step is as follows:
Figure BDA0002426768050000111
wherein the molar ratio of the compound shown in the formula (3) to HCl is 1: 0.1-10; the reaction temperature is 0-30 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one or any mixture of methanol, ethanol, n-butanol, isopropanol, dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane.
The second step is that: reacting an intermediate shown in a formula (A) and a formula (B) with R under the action of alkali4X and R5And carrying out substitution reaction on X to obtain a chiral bidentate nitrogen phosphine ligand Rong-Phos formula (S) -1 and a chiral bidentate nitrogen phosphine ligand Rong-Phos formula (R) -1.
The reaction scheme of the second step is as follows:
Figure BDA0002426768050000121
wherein, the intermediate
Figure BDA0002426768050000122
R4、R5The molar ratio of the alkali to the alkali is 1: 0.1-10: 2-20; the reaction temperature is 0-100 ℃; the reaction time is 1 to 24 hours. The solvent can be one of acetonitrile, methanol, ethanol, n-butanol, isopropanol, dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane or any mixture thereof. The base in the reaction can be potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, potassium bicarbonate, sodium bicarbonate, triethylamine, diethylamine, potassium tert-butoxide and sodium tert-butoxide.
The invention also provides application of the chiral bidentate nitrogen phosphine ligand Rong-Phos in preparation of an iridium complex of the chiral bidentate nitrogen phosphine ligand Rong-Phos.
The invention also provides a high enantioselectivity preparation method of the chiral bidentate nitrogen phosphine ligand Rong-Phos and the ionic iridium complex thereof.
The invention provides a synthesis method of a chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex, namely a method for constructing a nitrogen chiral center high enantioselectivity of the chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex shown in a formula (2), which starts from a compound shown in a formula (1) and [ Ir (COD) Cl]2Dissolving the sodium salt and the sodium salt in a solvent, and stirring for reaction to prepare an optically pure Rong-Phos iridium complex shown in the formula (2); wherein the compound of formula (1) is as follows; the compound of the formula (1) is a compound of formula (S) -1 or formula (R) -1;
Figure BDA0002426768050000123
the Rong-Phos iridium complex of formula (2) comprises formula (S)C,RN)-2、(SC,SN)-2、(RC,SN)-2、(RC,RN) -2 in four configurations:
Figure BDA0002426768050000131
the synthesis method of the chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex comprises the following three methods:
the method comprises the following steps: the compound (S) -1 or (R) -1 is reacted with [ Ir (COD) Cl]2Reacting, adding H after the reaction is completed2O and NaX to respectively obtain a chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex with a single configuration, and a larger group R on a chiral carbon atom2And a larger group R on the nitrogen atom4In trans form, having the configuration of formula (S)C,RN) -2 and formula (R)C,SN) -2; the reaction formula is shown below.
Figure BDA0002426768050000132
Wherein, the compound of formula (1) and [ Ir (COD) Cl]2、H2The molar ratio of O to NaX is 1: 0.1-10: 100-1000: 0.1-10; the reaction temperature is 0-100 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one of dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane or any mixture thereof. NaX can be NaBARF or NaBF in the reaction4、NaPF6、NaCl。
The second method comprises the following steps: the compound (S) -1 or (R) -1, [ Ir (COD) Cl]2And NaX react together to respectively obtain a Rong-Phos iridium complex with a single configuration and a larger group R on a chiral carbon atom2And a larger group R on the nitrogen atom4Is in cis form and has the configuration as formula (S)C,SN) -2 and formula (R)C,RN) -2.
Figure BDA0002426768050000141
Wherein, the compound of formula (1) and [ Ir (COD) Cl]2The molar ratio of NaX to NaX is 1: 0.1-10; the reaction temperature is 0-100 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one of dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane or any mixture thereof. NaX can be NaBARF or NaBF in the reaction4、NaPF6、NaCl。
The third method comprises the following steps: Ming-Phos, i.e. a compound of formula (4) substituted by the nitrogen atom in the Rong-Phos preparation method, [ Ir (COD) Cl]2Reacting with NaX, and simultaneously obtaining two nitrogen chiral catalysts while keeping the carbon chiral center of Rong-Phos unchanged, and simultaneously obtaining two configurations, namely a Rong-Phos iridium complex of a pair of diastereoisomers; the compound of the formula (4) is a compound of formula (Sc, Rs) -4, (Sc, Ss) -4, (Rc, Rs) -4.
Figure BDA0002426768050000151
Wherein, the compound of formula (4) < CHEM > and [ Ir (COD) Cl]2The molar ratio of NaX to NaX is 1: 0.1-10; the reaction temperature is 0-100 ℃; the reaction time is 0.5 to 12 hours. The solvent can be one of dichloromethane, diethyl ether, dibutyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, 1, 4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, benzene, chlorobenzene, fluorobenzene, chloroform and n-hexane or any mixture thereof. NaX can be NaBARF or NaBF in the reaction4、NaPF6、NaCl。
In the above method of the invention, the sodium salt is NaBARF or NaBF4、NaPF6Or NaCl, wherein the solvent is dichloromethane, and the stirring reaction is as follows: under the inert gas atmosphere, at 0-50 DEG CStirring for 0.5-12 hours at the temperature range.
The chiral bidentate azaphosphine ligand Rong-Phos has a chiral factor: carbon-centered chirality, all with two optical isomers. The Rong-Phos iridium complex has two chiral factors: carbon-centered chirality and nitrogen-centered chirality, all of which have four optical isomers, including two pairs of enantiomers, i.e., carbon-centered chirality is R, nitrogen-centered chirality is R and carbon-centered chirality is S, nitrogen-centered chirality S is a pair of enantiomers; the chirality of the carbon center is S, the chirality of the nitrogen center is R, the chirality of the carbon center is R, and the chirality of the nitrogen center is S, which is the other pair of enantiomers. Therefore, the Rong-Phos iridium complex of the present invention actually contains the above four isomers. These isomers have the same chemical structural formula, but have different steric structures and optical rotation properties.
The invention also provides application of the Rong-Phos iridium complex in asymmetric catalytic hydrogenation of cyclic unsaturated carbonyl compounds, wherein the asymmetric hydrogenation of the cyclic unsaturated carbonyl compounds is realized by dissolving the cyclic unsaturated carbonyl compounds in toluene or 1, 2-dichloroethane and performing pressurized reaction in an environment of 1 atm-100 atm.
Preferably, the cyclic unsaturated carbonyl compound and the chiral bidentate phosphorane ligand hong-Phos iridium complex are present in a molar ratio of 0.0005 to 0.05: 1 is dissolved in toluene or 1, 2-dichloroethane, and the hydrogenation reaction of the cyclic unsaturated carbonyl compound is realized under the pressure reaction in the environment of 1 atm-100 atm.
The structure of the cyclic unsaturated carbonyl compound is as follows:
Figure BDA0002426768050000161
in the formula: x' C, O, NH or NR8;R7And R8Each is one of aryl, alkyl, alkaryl, aralkyl, or substituted derivatives thereof; n is 0,1, 2,3, 4.
The substituted derivative is: carboxylic acid, alkoxy, hydroxy, alkylmercapto, mercapto, or dialkyl:
the pressure reaction is as follows: reacting for 1-120 hours under hydrogen pressure.
In a specific embodiment, experiments prove that the Rong-Phos iridium complex prepared by the invention can obtain 99% of yield in hydrogenation reaction, and the ee value of the product can reach 99%. This result is already the best level for the substrates of the enones and, for the substrates of lactams, the best results obtained at present.
The invention overcomes the technical difficulties existing in the prior art. In the prior art, a method of phosphine on an ortho-position is adopted from chiral alpha-phenylethylamine, and in the method, a substituent on an alpha position of a benzene ring, namely carbon, can only be methyl or has no substituent, so that the technical limitation is large. The substantial technical breakthrough of the method of the invention can synthesize corresponding structures substituted by a plurality of different substituents at the position, and the effect is remarkable and excellent. The invention provides a technical innovation with extremely high difficulty, and no report is found at present.
The present invention also provides an asymmetric hydrogenation reaction of a cyclic unsaturated carbonyl compound by dissolving the cyclic unsaturated carbonyl compound and the iridium complex of formula (2) Rong-Phos as described above in toluene or 1, 2-dichloroethane and subjecting the resultant to a pressurized reaction in an atmosphere of 1atm to 100 atm.
The novel chiral bidentate nitrogen phosphine ligand Rong-Phos in the formula (1) and the ionic iridium complex thereof have carbon chiral centers and nitrogen chiral centers and are stable in properties. The invention also discloses a method for constructing the nitrogen atom center of the iridium complex with high enantioselectivity, and a pair of diastereomer catalysts with different nitrogen center chiralities of the iridium complex are applied to asymmetric hydrogenation of a cyclic unsaturated carbonyl compound, so that a remarkable excellent result is obtained. The invention also discloses a Rong-Phos iridium complex formula (2) which has carbon center chirality and nitrogen center chirality and is prepared by using the ligand with high enantioselectivity and a method thereof. The invention creatively constructs the Rong-Phos iridium complex with a nitrogen chiral center with high enantioselectivity and successfully applies the Rong-Phos iridium complex to the catalysis of the asymmetric hydrogenation reaction of five-membered cyclic unsaturated carbonyl compounds, and the Rong-Phos iridium complex with a pair of diastereoisomers can respectively obtain products with R configuration and S configuration with high enantioselectivity, so that the invention becomes a successful case for solving the chemical problem of synthesizing a pair of enantiomers by using a ligand with one configuration, and the iridium complex also obtains excellent reaction activity and enantioselectivity in the asymmetric hydrogenation reaction of other cyclic unsaturated carbonyl compounds, thereby having scientific research value and wide application prospect.
Detailed Description
The present invention will be described in further detail with reference to the following specific examples, and the procedures, conditions, reagents, experimental methods and the like for carrying out the present invention are general knowledge and common general knowledge in the art except for those specifically mentioned below, and the present invention is not particularly limited thereto.
The following example provides a synthetic scheme for the aforementioned Rong-Phos Compound 1, specifically:
example 1
Figure BDA0002426768050000171
(SC,RS) Synthesis of (E) -6a
Referring to method one, a 50mL dry single neck bottle was charged under helium atmosphere
Figure BDA0002426768050000172
(1mmol) and dried tetrahydrofuran solvent (10mL), stirred at-40 ℃ for 10 min, and n-butyllithium (1.6eq.,1mL,1.6M) was added dropwise. Stirring was continued for 1 hour, methyl triflate (1.6mmol) was added, thenStirred for 30 minutes. The reaction was then quenched with saturated ammonium chloride solution. Then carrying out liquid separation, extraction, drying, spin-drying of the solvent and column chromatography purification to obtain the product
Figure BDA0002426768050000173
The yield was 91%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.76-7.69 (m,1H), 7.37-7.21 (m,11H), 7.18-7.11 (m,1H), 7.11-7.04 (m,1H),5.43(d, J ═ 13.6Hz,1H),2.62(s,3H),1.13(s,9H),1.01(s,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -16.37 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 145.99(d, J ═ 24.4Hz),137.31(d, J ═ 10.6Hz),137.08(d, J ═ 2.7Hz),136.99(d, J ═ 3.4Hz),135.39,133.92(d, J ═ 6.9Hz),133.76(d, J ═ 7.1Hz),129.57(d, J ═ 3.6Hz), 128.67-128.43 (m),128.39,127.39,73.23(d, J ═ 28.4Hz),58.93,38.68,32.84(d, J ═ 1.6Hz),28.97(d, J ═ 1.8Hz),24.75 high resolution mass spectrum theoretical data C, c.7528H37NOPS([M+H]+) 466.2328, experimental data 466.2328.
Example 2
Figure BDA0002426768050000181
(SC,RS) Synthesis of (E) -6b
For specific operation, reference is made to example 1, starting from
Figure BDA0002426768050000182
The yield was 86%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.76-7.71 (m,1H), 7.43-7.39 (m,1H), 7.35-7.29 (m,9H), 7.28-7.23 (m,3H),5.47(d, J ═ 13.1Hz,1H),2.84(s,3H), 1.88-1.73 (m,6H), 1.63-1.48 (m,9H),1.08(s,9H), phosphorus nuclear magnetic spectrum (202MHz, CDCl-3) δ -18.14, carbon nuclear magnetic (126MHz, Chloroform-d) δ 143.89(d, J, 25.9Hz),137.80(d, J, 11.9Hz),137.33(d, J, 12.3Hz),137.15(d, J, 10.8Hz),136.16(d, J, 1.8Hz),134.10(d, J, 20.0Hz),133.45(d, J, 19.0Hz),129.98(d, J, 4.1Hz),128.67,128.51-128.37 (m),128.33,127.14,73.65(d, J, 27.5Hz),58.66,40.68(d, J, 1.6Hz),40.04,30.10(d, J, 1.4Hz),28.62,24.75(d, J, 2.0) theoretical high-resolution C data34H43NOPS([M+H]+) 544.2797, experimental data 544.2794.
Example 3
Figure BDA0002426768050000183
(SC,RS) Synthesis of-6 c
For specific operation, reference is made to example 1, starting from
Figure BDA0002426768050000184
The yield was 76%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.52-7.12 (m,14H),5.23(t, J ═ 10.2Hz,1H),2.64(s,3H), 2.15-2.03 (m,1H), 2.00-1.88 (m,1H), 1.84-1.75 (m,1H), 1.61-1.50 (m,1H), 1.40-1.27 (m,2H), 1.22-0.91 (m,13H), 0.85-0.78 (m,1H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -18.64 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 145.32(d, J ═ 25.4Hz),137.04(d, J ═ 12.1Hz), 136.80-136.51 (m),135.02,134.53(d, J ═ 20.7Hz),133.57(d, J ═ 18.8Hz),129.16,128.89,128.66-128.32 (m),127.15,126.86(d, J ═ 4.9Hz),70.10(d, J ═ 26.3Hz),58.61,38.51,30.75,29.95, 26.43-26.01 (m),25.33,24.41(d, J ═ 2.7Hz), high resolution mass spectrometry theoretical data C30H38NNaOPS([M+Na]+) 514.2304, experimental data 514.2297.
Example 4
Figure BDA0002426768050000191
(SC,RS) Synthesis of-6 d
For specific operation, reference is made to example 1, starting from
Figure BDA0002426768050000192
The yield was 93%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.52-7.12 (m,14H),5.23(t, J ═ 10.2Hz,1H),2.64(s,3H), 2.15-2.03 (m,1H), 2.00-1.88 (m,1H), 1.84-1.75 (m,1H), 1.61-1.50 (m,1H), 1.40-1.27 (m,2H), 1.22-0.91 (m,13H), 0.85-0.78 (m,1H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -18.64 carbon spectrum nuclear magnetic δ 145.32(d, J-25.4 Hz),137.04(d, J-12.1 Hz), 136.80-136.51 (m),135.02,134.53(d, J-20.7 Hz),133.57(d, J-18.8 Hz),129.16,128.89,128.66-128.32 (m),127.15,126.86(d, J-4.9 Hz),70.10(d, J-26.3 Hz),58.61,3851,30.75,29.95, 26.43-26.01 (m),25.33,24.41(d, J ═ 2.7Hz)31H42NNaOPS([M+Na]+) 530.2617, experimental data 530.2602.
Example 5
Figure BDA0002426768050000193
(SC,RS) Synthesis of-6 e
For specific operation, reference is made to example 1, starting from
Figure BDA0002426768050000194
The yield was 82%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.91-7.86 (m,1H), 7.46-7.40 (m,1H), 7.36-7.21 (m,12H),5.76(d, J ═ 13.4Hz,1H),2.77(d, J ═ 0.9Hz,3H),1.90(dq, J ═ 14.6,7.3Hz,1H), 1.48-1.38 (m,1H),1.16(s,9H),1.08(s,3H),0.91(t, J ═ 7.4Hz,3H),0.80(dq, J ═ 13.9,7.3Hz,1H),0.57(t, J ═ 7.4Hz,3H), phosphorus nuclear magnetic spectrum (202MHz, cl ═ 7.4Hz,3H), phosphorus nuclear magnetic spectrum (202MHz, CDCl ═ 1H), and the like3) δ -18.44 carbon nuclear magnetic spectroscopy (126MHz, Chloroform-d) δ 144.80(d, J ═ 25.5Hz),137.97(d, J ═ 11.5Hz),137.48(d, J ═ 11.7Hz),137.10(d, J ═ 10.9Hz),136.21(d, J ═ 1.9Hz), 134.06-133.14 (m),130.30(d, J ═ 4.1Hz), 128.92-128.21 (m),127.25,68.85(d, J ═ 27.4Hz),59.12,42.86,31.44(d, J ═ 2.2Hz),29.00(d, J ═ 2.9Hz),28.63,25.13,22.01(d, J ═ 2.2Hz),8.24,7.66, high resolution theoretical data C, mass spectrometry, and others30H40NOPS([M+H]+) 516.2460, experimental data 516.2452.
Example 6
Figure BDA0002426768050000201
(SC,RS) Synthesis of-6 f
For specific operation, reference is made to example 1, starting from
Figure BDA0002426768050000202
The yield was 83%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.99-7.92 (m,1H), 7.44-7.19 (m,13H),5.77(d, J ═ 13.9Hz,1H),2.73(s,3H), 1.66-1.45 (m,6H), 1.24-1.14 (m,9H),0.71(t, J ═ 7.5Hz,9H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) Delta-18.23. carbon spectrum nucleusMagnetic (126MHz, Chloroform-d) δ 144.94(d, J ═ 25.6Hz),138.13(d, J ═ 11.4Hz),137.46(d, J ═ 11.2Hz),136.92(d, J ═ 11.0Hz),136.26(d, J ═ 1.8Hz),133.87(d, J ═ 20.0Hz),133.31(d, J ═ 18.8Hz),130.90(d, J ═ 3.8Hz), 128.93-128.16 (m),127.39,68.88(d, J ═ 27.4Hz),59.16,45.07,32.11(d, J ═ 2.3Hz),27.27(d, J ═ 2.1Hz),25.27,8.86. high resolution theoretical data C of mass spectrum31H42NNaOPS([M+Na]+) 530.2617, experimental data 530.2599.
Example 7
Figure BDA0002426768050000203
(SC,RS) Synthesis of-6 g
For specific operation, reference is made to example 1, starting from
Figure BDA0002426768050000204
The yield was 85%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.55(ddd, J ═ 7.9,4.5,1.3Hz,1H), 7.43-7.37 (m,1H), 7.33-7.29 (m,3H), 7.23-7.14 (m,6H), 7.06-6.98 (m,5H),6.59(s,1H),3.55(s,3H),2.71(s,3H),1.30(s,18H),1.16(s,9H) phosphorus nuclear magnetic spectrum (122MHz, CDCl)3) Delta-17.86 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) delta 158.14,146.92(d, J ═ 23.6Hz),142.89,137.82(d, J ═ 11.9Hz),136.11(d, J ═ 3.6Hz),136.01,134.92,133.57(d, J ═ 19.7Hz),132.85,128.85,128.71,128.46,128.41,128.38,128.26(d, J ═ 7.1Hz),127.43,64.10,58.57,35.67,32.07,24.00 high resolution mass spectrometry theoretical data C39H51NO2PS([M+H]+) 628.3370; found,628.3373, experimental data 628.3373.
Example 8
Figure BDA0002426768050000211
Synthesis of (S) -1a
Referring to method one, a 50mL dry single neck bottle was charged under helium atmosphere
Figure BDA0002426768050000212
(1mmol) and a methanol solvent (5mL), concentrated hydrochloric acid (5.0eq.) was added dropwise, and the mixture was stirred at room temperature for 1 hour. Then ethyl acetate is used againThe solution is diluted. Then washing with saturated sodium bicarbonate solution, washing with saturated salt solution, extracting, drying, spin-drying solvent and purifying by column chromatography to obtain
Figure BDA0002426768050000213
The yield was 96%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.62-7.58 (m,1H), 7.44-7.26 (m,10H), 7.23-7.18 (m,1H), 7.17-7.13 (m,1H),4.71(d, J ═ 8.9Hz,1H),1.96(s,3H),1.07(s,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.95 carbon nuclear magnetic (126MHz, Chloroform-d) δ 147.69(d, J ═ 23.6Hz),137.95(d, J ═ 12.7Hz),137.72(d, J ═ 2.8Hz),137.62(d, J ═ 4.2Hz),134.86(d, J ═ 2.1Hz),133.89(d, J ═ 20.0Hz),133.56(d, J ═ 19.1Hz),128.85,128.64-128.09 (m),127.54(d, J ═ 5.3Hz),126.78,69.20(d, J ═ 23.7Hz),36.12,35.16,27.55(d, J ═ 3.0Hz), high resolution mass spectrometry theoretical data C24H29NP([M+H]+) 362.2032, experimental data 362.2037.
Example 9
Figure BDA0002426768050000214
Synthesis of (S) -1b
Specific operation with reference to example 8, the starting material used was
Figure BDA0002426768050000215
The yield was 95%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.56-7.49 (m,1H), 7.41-7.24 (m,11H), 7.21-7.17 (m,1H), 7.16-7.11 (m,1H),4.54(d, J ═ 9.0Hz,1H), 1.99-1.92 (m,6H),1.90(s,3H), 1.71-1.52 (m,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.33, carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 146.66(d, J ═ 23.9Hz),138.15(d, J ═ 12.7Hz),137.78(d, J ═ 13.0Hz),137.51(d, J ═ 11.5Hz),134.72,133.93(d, J ═ 20.0Hz),133.53(d, J ═ 19.1Hz), 128.76-128.15 (m),127.88(d, J ═ 5.3Hz),126.69,70.10(d, J ═ 23.5Hz),39.36(d, J ═ 3.1Hz),37.88,37.12,35.04,28.6830H35NP([M+H]+) 440.2502, experimental data 440.2505.
Example 10
Figure BDA0002426768050000221
Synthesis of (S) -1c
Specific operation with reference to example 8, the starting material used was
Figure BDA0002426768050000222
The yield was 91%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.52-7.12 (m,14H),5.23(t, J ═ 10.2Hz,1H),2.64(s,3H), 2.15-2.03 (m,1H), 2.00-1.88 (m,1H), 1.84-1.75 (m,1H), 1.61-1.50 (m,1H), 1.40-1.27 (m,2H), 1.22-0.91 (m,4H), 0.85-0.78 (m,1H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -18.64 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 145.32(d, J ═ 25.4Hz),137.04(d, J ═ 12.1Hz), 136.80-136.51 (m),135.02,134.53(d, J ═ 20.7Hz),133.57(d, J ═ 18.8Hz),129.16,128.89,128.66-128.32 (m),127.15,126.86(d, J ═ 4.9Hz),70.10(d, J ═ 26.3Hz),58.61,38.51,30.75,29.95, 26.43-26.01 (m),24.41(d, J ═ 2.7Hz), high resolution mass spectrometry theoretical data C, J, and C26H31NP([M+H]+) 388.2189, experimental data 388.2190.
Example 11
Figure BDA0002426768050000223
Synthesis of (S) -1d
Specific operation with reference to example 8, the starting material used was
Figure BDA0002426768050000224
The yield was 90%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.52-7.12 (m,14H),5.23(t, J ═ 10.2Hz,1H),2.64(s,3H), 2.15-2.03 (m,1H), 2.00-1.88 (m,1H), 1.84-1.75 (m,1H), 1.61-1.50 (m,1H), 1.40-1.27 (m,2H), 1.22-0.91 (m,4H), 0.85-0.78 (m,1H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -18.64 carbon spectrum nuclear magnetism δ 145.32(d, J ═ 25.4Hz),137.04(d, J ═ 12.1Hz), 136.80-136.51 (m),135.02,134.53(d, J ═ 20.7Hz),133.57(d, J ═ 18.8Hz),129.16,128.89,128.66-128.32 (m),127.15,126.86(d, J ═ 4.9Hz),70.10(d, J ═ 26.3Hz),58.61,38.51,30.75,29.95, 26.43-26.01 (m),24.41(d, J ═ 2.7Hz), high resolution mass spectrum theoretical data C, d, J ═ 2.7Hz27H35NP([M+H]+) 404.2502, experimental data 404.2505.
Example 12
Figure BDA0002426768050000225
Synthesis of (S) -1e
Specific operation with reference to example 8, the starting material used was
Figure BDA0002426768050000231
The yield was 93%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.91-7.86 (m,1H), 7.46-7.40 (m,1H), 7.36-7.21 (m,12H),5.76(d, J ═ 13.4Hz,1H),2.77(d, J ═ 0.9Hz,3H),1.90(dq, J ═ 14.6,7.3Hz,1H), 1.48-1.38 (m,1H),1.08(s,3H),0.91(t, J ═ 7.4Hz,3H),0.80(dq, J ═ 13.9,7.3Hz,1H),0.57(t, J ═ 7.4Hz,3H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -18.44 carbon nuclear magnetic spectroscopy (126MHz, Chloroform-d) δ 144.80(d, J ═ 25.5Hz),137.97(d, J ═ 11.5Hz),137.48(d, J ═ 11.7Hz),137.10(d, J ═ 10.9Hz),136.21(d, J ═ 1.9Hz), 134.06-133.14 (m),130.30(d, J ═ 4.1Hz), 128.92-128.21 (m),127.25,68.85(d, J ═ 27.4Hz),59.12,42.86,31.44(d, J ═ 2.2Hz),29.00(d, J ═ 2.9Hz),28.63,22.01(d, J ═ 2.2Hz),8.24,7.66, high resolution theoretical data C26H33NP([M+H]+) 390.2345, experimental data 390.2341.
Example 13
Figure BDA0002426768050000232
Synthesis of (S) -1f
Specific operation with reference to example 8, the starting material used was
Figure BDA0002426768050000233
The yield was 95%. Hydrogen nuclear magnetic (500MHz, Chloroform-d) delta 7.99-7.92 (m,1H), 7.44-7.19 (m,13H),5.77(d, J ═ 13.9Hz,1H),2.73(s,3H), 1.66-1.45 (m,6H), 0.71(t, J ═ 7.5Hz,9H), phosphorus nuclear magnetic (202MHz, CDCl)3) δ -18.23 carbon nuclear magnetic spectroscopy (126MHz, Chloroform-d) δ 144.94(d, J ═ 25.6Hz),138.13(d, J ═ 11.4Hz),137.46(d, J ═ 11.2Hz),136.92(d, J ═ 11.0Hz),136.26(d, J ═ 1.8Hz),133.87(d, J ═ 20.0Hz),133.31(d, J ═ 18.8Hz),130.90(d, J ═ 3.8Hz), 128.93-128.16 (m),127.39,68.88(d, J ═ 27.4Hz),59.16,45.07,32.11(d, J ═ 2.3Hz),27.27(d, J ═ 25 ═ 128.16(m)2.1Hz),8.86. high resolution Mass Spectrometry theoretical data C27H35NP([M+H]+) 404.2502, experimental data 404.2502.
Example 14
Figure BDA0002426768050000234
Synthesis of (S) -1g
Specific operation with reference to example 8, the starting material used was
Figure BDA0002426768050000241
The yield was 88%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.68-7.63 (m,1H), 7.42-7.23 (m,11H), 7.18-7.11 (m,3H), 7.00-6.94 (m,1H),5.70(d, J ═ 7.9Hz,1H),3.84(s,1H),3.62(s,3H),2.32(s,3H),1.36(s,18H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) Delta-17.63 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) delta 158.03,149.00(d, J ═ 23.3Hz),142.93,137.80(d, J ═ 11.2Hz),136.81,136.72,135.43(d, J ═ 13.2Hz), 134.33-134.26 (m), 134.02-133.43 (m),129.40,128.65-128.25 (m),127.42(d, J ═ 5.4Hz),126.96,126.02(d, J ═ 2.1Hz),65.61(d, J ═ 24.2Hz),64.05,35.70,35.05,32.12 high resolution theoretical data C, mass spectrum35H43NOP([M+H]+) 524.3077, experimental data 524.3085.
Example 15
Figure BDA0002426768050000242
Synthesis of (S) -1b
Referring to method two, a 50mL dry single neck bottle was charged under helium atmosphere
Figure BDA0002426768050000243
(1mmol) and a methanol solvent (5mL), concentrated hydrochloric acid (5.0eq.) was added dropwise, and the mixture was stirred at room temperature for 1 hour. The solution was then diluted with ethyl acetate. Then washing with saturated sodium bicarbonate solution, washing with saturated salt water, extracting, drying and spin-drying the solvent to obtain a hydrolysis crude product. The crude product and dry 1, 2-dichloroethane (5mL), paraformaldehyde (1.5eq.), and sodium triacetoxyborohydride (3.0eq.) and dry 1, 2-dichlorohydride (3.0eq.) were added under a helium atmosphere in a 50mL dry single neck flaskEthane solution (5 mL). Stirring at room temperature for 12 hours, then filtering, spin-drying the solvent, and purifying by column chromatography to obtain
Figure BDA0002426768050000244
The yield was 81%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.56-7.49 (m,1H), 7.41-7.24 (m,11H), 7.21-7.17 (m,1H), 7.16-7.11 (m,1H),4.54(d, J ═ 9.0Hz,1H), 1.99-1.92 (m,6H),1.90(s,3H), 1.71-1.52 (m,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.33 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 146.66(d, J ═ 23.9Hz),138.15(d, J ═ 12.7Hz),137.78(d, J ═ 13.0Hz),137.51(d, J ═ 11.5Hz),134.72,133.93(d, J ═ 20.0Hz),133.53(d, J ═ 19.1Hz), 128.76-128.15 (m),127.88(d, J ═ 5.3Hz),126.69,70.10(d, J ═ 23.5Hz),39.36(d, J ═ 3.1Hz),37.88,37.12,35.04,28.6830H35NP([M+H]+) 440.2502, experimental data 440.2505.
Example 16
Figure BDA0002426768050000251
Synthesis of (S) -1g
Referring to example 15, the starting material used was n-butyraldehyde in a yield of 78%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.64-7.49 (m,1H), 7.41-7.22 (m,11H), 7.16-7.11 (m,2H),4.74(d, J ═ 9.0Hz,1H), 1.99-0.62 (m,24H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.94 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 146.66(d, J ═ 23.9Hz),138.15(d, J ═ 12.7Hz),137.78(d, J ═ 13.0Hz),137.51(d, J ═ 11.5Hz),134.72,133.93(d, J ═ 20.0Hz),133.53(d, J ═ 19.1Hz), 128.76-128.15 (m),127.88(d, J ═ 5.3Hz),126.69,70.10(d, J ═ 23.5Hz),50.81,39.36(d, J ═ 3.1Hz),37.88,37.12,35.04,28.68,20.1013.18, high resolution mass spectrum theoretical data C33H41NP([M+H]+) 482.2971, experimental data 482.2977.
Example 17
Figure BDA0002426768050000252
Synthesis of (S) -1h
In specific operation with reference to example 15, benzaldehyde was used as the starting material in a yield of83 percent. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.75-7.62 (m,1H), 7.49-7.10 (m,18H),4.71(d, J ═ 8.6Hz,1H),3.23(d, J ═ 13.2Hz,1H),3.01(d, J ═ 13.2Hz,1H), 2.04-1.91 (m,6H), 1.70-1.56 (m,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.03 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 147.29(d, J ═ 23.8Hz),141.50,138.27-137.53 (m),134.61(d, J ═ 1.9Hz),134.05(d, J ═ 20.1Hz),133.54(d, J ═ 19.1Hz), 128.79-127.69 (m),126.60(d, J ═ 15.4Hz),68.18(d, J ═ 23.2Hz),52.13,39.37(d, J ═ 3.0Hz),38.07,37.17,28.72, high resolution mass spectrometry theoretical data C36H39NP([M+H]+) 516.2815, experimental data 516.2817.
Example 18
Figure BDA0002426768050000253
Synthesis of (S) -1b
Reference method three, adding to a 50mL dry single-neck bottle under helium atmosphere
Figure BDA0002426768050000254
(1mmol) and a methanol solvent (5mL), concentrated hydrochloric acid (5.0eq.) was added dropwise, and the mixture was stirred at room temperature for 1 hour. The solution was then diluted with ethyl acetate. Then washing with saturated sodium bicarbonate solution, washing with saturated salt water, extracting, drying and spin-drying the solvent to obtain a hydrolysis crude product. The crude product and dry acetonitrile (5mL), methyl iodide (1.5eq), and potassium carbonate (3.0eq.) were added under a helium atmosphere in a 50mL dry single-neck flask. Stirring at 80 deg.C for 12 hr, suction filtering, spin drying solvent, and purifying by column chromatography to obtain
Figure BDA0002426768050000261
The yield was 82%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.56-7.49 (m,1H), 7.41-7.24 (m,11H), 7.21-7.17 (m,1H), 7.16-7.11 (m,1H),4.54(d, J ═ 9.0Hz,1H), 1.99-1.92 (m,6H),1.90(s,3H), 1.71-1.52 (m,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.33 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 146.66(d, J ═ 23.9Hz),138.15(d, J ═ 12.7Hz),137.78(d, J ═ 13.0Hz),137.51(d, J ═ 11.5Hz),134.72,133.93(d, J ═ 20.0Hz),133.53(d, J ═ 19.1Hz), 128.76-128.15 (m),127.88(d, J ═ 5.3Hz),126.69,70.10(d, J ═ 23.5Hz),39.36(d, J ═ 3.1Hz),37.88,37.12,35.04,28.6830H35NP([M+H]+) 440.2502, experimental data 440.2505.
Example 19
Figure BDA0002426768050000262
Synthesis of (S) -1g
Referring to example 18, the starting material used was iodobutane, which was obtained in 82% yield. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.64-7.49 (m,1H), 7.41-7.22 (m,11H), 7.16-7.11 (m,2H),4.74(d, J ═ 9.0Hz,1H), 1.99-0.62 (m,24H), phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.94 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 146.66(d, J ═ 23.9Hz),138.15(d, J ═ 12.7Hz),137.78(d, J ═ 13.0Hz),137.51(d, J ═ 11.5Hz),134.72,133.93(d, J ═ 20.0Hz),133.53(d, J ═ 19.1Hz), 128.76-128.15 (m),127.88(d, J ═ 5.3Hz),126.69,70.10(d, J ═ 23.5Hz),50.81,39.36(d, J ═ 3.1Hz),37.88,37.12,35.04,28.68,20.1013.18, high resolution mass spectrum theoretical data C33H41NP([M+H]+) 482.2971, experimental data 482.2977.
Example 20
Figure BDA0002426768050000263
Synthesis of (S) -1h
Referring to example 18, the starting material used was benzyl bromide in 81% yield. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.75-7.62 (m,1H), 7.49-7.10 (m,18H),4.71(d, J ═ 8.6Hz,1H),3.23(d, J ═ 13.2Hz,1H),3.01(d, J ═ 13.2Hz,1H), 2.04-1.91 (m,6H), 1.70-1.56 (m,9H). phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ -17.03 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 147.29(d, J ═ 23.8Hz),141.50,138.27-137.53 (m),134.61(d, J ═ 1.9Hz),134.05(d, J ═ 20.1Hz),133.54(d, J ═ 19.1Hz), 128.79-127.69 (m),126.60(d, J ═ 15.4Hz),68.18(d, J ═ 23.2Hz),52.13,39.37(d, J ═ 3.0Hz),38.07,37.17,28.72, high resolution mass spectrometry theoretical data C36H39NP([M+H]+) 516.2815, experimental data 516.2817.
The following example provides a synthetic scheme for the Rong-Phos iridium complex 2 with different stereo structures, specifically:
example 21
Figure BDA0002426768050000271
(SC,RN) Synthesis of (E) -2a
Reference method one, in a 50mL dry Schlenk reaction flask, add under helium atmosphere
Figure BDA0002426768050000272
(0.5mmol)、[Ir(COD)Cl]2(0.25mmol) and dry dichloromethane solvent (10mL) were stirred at 50 ℃ for 6 hours, TLC was sampled and heating was stopped when ligand was completely complexed and the system was allowed to cool to room temperature naturally. Adding H under vigorous stirring2O (5mL) and NaBARF (661mg) were added and the reaction was continued for 1 hour. Then separating the organic phase with Na2SO4Drying, spin-drying solvent, and purifying by column chromatography to obtain
Figure BDA0002426768050000273
The yield was 80%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) δ 8.09-7.98 (m,2H), 7.79-7.71 (m,8H), 7.64-7.42 (m,13H), 7.24-7.19 (m,1H), 7.18-7.11 (m,2H), 4.84-4.76 (m,1H),4.29(d, J ═ 6.5Hz,1H), 4.11-4.01 (m,2H),3.47(H, J ═ 3.4,2.5Hz,2H),2.65(d, J ═ 6.0Hz,3H), 2.51-2.39 (m,1H), 2.33-2.16 (m,3H), 2.07-1.99 (m,1H), 1.95-1.83 (m,2H), 1.81-1.70 (m,1H), 1.202H, 9-1H, 9H, 1 cl), 1H, 2H, 1H, p (cl), p, cl, p, c, p3) δ 5.39. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.38-161.05 (m),139.52(d, J15.4 Hz),136.30,135.12(d, J10.0 Hz),134.93,134.81(d, J4.4 Hz),132.53(d, J9.7 Hz),132.26(d, J2.5 Hz),131.91,131.61(d, J2.3 Hz),131.47,131.29(d, J2.5 Hz),130.56(d, J6.7 Hz),129.43(d, J10.9 Hz), 129.32-129.20 (m), 129.14-128.92 (m), 128.84-128.67 (m), 128.58-128.43 (m),128.32,127.81,125.64,123.47,123.25,122.89,121.30,92.84(d, J8.6 Hz), 5(d, J15.2), 80.01, 3.31 Hz), 75.31 Hz, 31.31 Hz, 3.3.3.3 Hz, 3.3.3 Hz, 3.31 Hz), 75-75 Hz, 31.7, 3.3.3.3, 3.3, 3.3.3, 3.3Hz, 3, Hz,332H40NPIr+([M-BArF]+) 662.25221, experimental data 662.25206.
Example 22
Figure BDA0002426768050000281
(SC,RN) Synthesis of (E) -2b
Specific operation with reference to example 21, starting materials used were
Figure BDA0002426768050000282
The yield was 85%. Nuclear magnetic spectrum (500MHz, Chloroform-d) δ 8.09-8.01 (m,2H), 7.77-7.73 (m,8H), 7.65-7.41 (m,13H), 7.23-7.11 (m,3H), 4.81-4.73 (m,1H), 4.32-4.23 (m,1H), 4.11-4.02 (m,1H), 3.93-3.88 (m,1H), 3.54-3.46 (m,2H),2.65(d, J ═ 5.9Hz,3H), 2.56-2.44 (m,1H), 2.34-2.17 (m,3H), 2.13-2.07 (m,4H), 2.03-1.89 (m,4H), 1.83-1.73 (m,7H), 1.66-1.58 (m, 58H), phosphorus (cl), CDCl, 2H),1 MHz-1.58 (m,1H), 1H, 58(m, 202H), CDCl3) δ 4.80. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.46-161.01 (m),138.55(d, J ═ 15.7Hz),136.28,135.17-134.64 (m),132.53(d, J ═ 9.6Hz),132.22(d, J ═ 2.5Hz),131.77,131.57(d, J ═ 2.3Hz),131.33,131.20(d, J ═ 2.4Hz),130.58(d, J ═ 6.6Hz), 129.53-128.39 (m),127.81,125.65,123.48,123.10,121.31,117.79-117.11 (m),91.24(d, J ═ 8.1Hz),81.96(d, J ═ 16.3Hz),81.43(d, J ═ 3.1Hz),66.75,63.90,43.42,41.33, mass spectrum 37.54,36.21,34.23(d, J ═ 4.4Hz),32.84 (d, J ═ 28.84, 60 ═ 2.27.27 Hz), theoretical high-resolution data (d, J ═ 2.26 Hz, J ═ 2.27.27 Hz), and theoretical data (d, J ═ 2.3.3 Hz)38H46NPIr+([M-BArF]+) 740.29916, experimental data 740.29883.
Example 23
Figure BDA0002426768050000283
(SC,RN) Synthesis of (E) -2c
Specific operation with reference to example 21, starting materials used were
Figure BDA0002426768050000284
The yield was 87%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 7.77-7.72 (m,9H), 7.70-7.62 (m,2H), 7.59-7.35 (m,14H), 7.17-7.11 (m,1H) 4.79-4.70 (m,1H), 4.54-4.44 (m,1H), 4.40-4.30 (m,1H), 4.13-4.05 (m,1H), 3.43-3.31 (m,1H), 3.27-3.18 (m,1H),2.57(d, J ═ 6.0Hz,3H), 2.46-2.19 (m,2H), 2.16-1.96 (m,4H), 1.95-1.75 (m,3H), 1.33-1.25 (m,5H), 1.19-0.99 (m,2H), 0.65-0.53 (m,1H), 0.53-0.44 (m,1H), 0.33-0.21 (m,1H), nuclear magnetic phosphorus spectrum (CDCl (202MHz, 1H)3) δ 5.02 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.46-160.92 (m),140.99(d, J ═ 14.7Hz),135.34(d, J ═ 2.0Hz),134.80,134.21(d, J ═ 10.9Hz),133.75(d, J ═ 10.0Hz),133.28(d, J ═ 11.4Hz),132.13(d, J ═ 2.5Hz), 132.00-131.85 (m),130.84(d, J ═ 7.1Hz), 129.89-128.36 (m),127.80,125.63,123.47,122.76,122.39,121.30,117.81-117.13 (m),94.07(d, J ═ 11.5Hz),90.51(d, J ═ 12.5Hz), 368 (d, J ═ 5.1Hz),69.50,6, 44.92(d, J ═ 2.6), 40.89, 3632 (d, J ═ 19.19 Hz), 28.88.25.25 Hz), 3619 (d, J ═ 25.38 Hz),40.89, 27, 25, 15, 27, 25, 15, 27, 18, 27, 25, 27, 18, 27, 25,3, 18, Hz, 18, Hz, 1834H42NPIr+([M-BArF]+) 688.26786, experimental data 688.26744.
Example 24
Figure BDA0002426768050000291
(SC,RN) Synthesis of (E) -2d
Specific operation with reference to example 21, starting materials used were
Figure BDA0002426768050000292
The yield was 82%. Nuclear magnetic resonance (500MHz, Chloroform-d) δ 8.08-8.00 (m,2H), 7.80-7.72 (m,8H), 7.65-7.58 (m,1H), 7.57-7.42 (m,12H), 7.26-7.20 (m,1H), 7.19-7.10 (m,2H), 4.82-4.75 (m,1H), 4.31-4.24 (m,1H),4.12(d, J ═ 2.3Hz,1H), 4.07-3.99 (m,1H), 3.54-3.48 (m,1H), 3.47-3.42 (m,1H),2.67(d, J ═ 6.0Hz,3H), 2.50-2.39 (m,1H), 2.33-2.13 (m,2H),2.84 (m,1H), 3.19H, 3.85 (m,1H), 3.18H, 3H, 3.18H, 3.7.3H, 3.18(m,1H), 2.3H, 3H, 3.3H, 3H, 3.7.3H, 1H, 3H, 1H, 3H, 1H, 2.3H, 1H, 3H, 1H, 3H, 1H, 3H, 2H, 3H, 1H, 3H, 1H, 2H, 1H, 2H, 1H, 3H, 1H, 2H, 1H, 2H, 1H, 2H, 1H, 2H, 1H, 2H, 1H, 2H, 1H, 2H3) δ 4.93. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.45-160.78 (m),139.38(d, J ═ 15.5Hz),136.35,135.07(d, J ═ 10.1Hz),134.91,134.81,132.59(d, J ═ 9.6Hz),132.26(d, J ═ 2.5Hz),131.99,131.62-131.52 (m),131.26(d, J ═ 2.6Hz),130.53(d, J ═ 6.7Hz), 129.69-1 (m)28.35(m),127.81,125.64,123.48(d, J ═ 2.7Hz),123.13,121.31,117.96-116.94 (m),92.46(d, J ═ 8.3Hz),84.09(d, J ═ 15.7Hz),79.96(d, J ═ 2.8Hz),66.56,63.72,43.65,41.19(d, J ═ 2.3Hz),38.62,33.26(d, J ═ 3.9Hz),31.80,31.51,30.48(d, J ═ 2.6Hz),30.33,30.16,29.71,27.70(d, J ═ 2.8Hz),26.55(d, J ═ 2.9Hz),25.82,23.36,14.00. high resolution mass spectrometry theoretical data c.0035H46NPIr+([M-BArF]+) 704.29916, experimental data 704.29831.
Example 25
Figure BDA0002426768050000301
(SC,RN) Synthesis of (E) -2e
Specific operation with reference to example 21, starting materials used were
Figure BDA0002426768050000302
The yield was 89%. Nuclear magnetic spectrum (500MHz, Chloroform-d) delta 8.09-7.98 (m,2H), 7.84-7.70 (m,9H), 7.67-7.42 (m,12H), 7.26-7.13 (m,3H), 4.87-4.78 (m,1H),4.25(s,1H), 4.22-4.16 (m,1H), 4.02-3.92 (m,1H), 3.51-3.36 (m,2H),2.65(d, J ═ 5.5Hz,3H),2.47(m,1H), 2.31-2.13 (m,5H), 2.11-1.94 (m,2H), 1.90-1.78 (m,1H), 1.69-1.34 (m,4H), 1.23-1.14 (m,2H), 1.01-0.84 MHz, 0.162H, 84 cl), 2H, CDCl, 1H, 1MHz, 1H, 2H, phosphorus (cl), c, cl, c, cl, c, H, c, m, c, m, c, H, m, c, m, c3) δ 5.96 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.41-161.03 (m),139.37(d, J-15.5 Hz),136.41,134.82(t, J-6.3 Hz),132.46(d, J-9.7 Hz),132.20(d, J-2.4 Hz), 131.73-131.05 (m),130.38(d, J-6.6 Hz), 129.88-128.23 (m),127.82,125.65,124.11,123.75,123.48,121.32,117.47(p, J-4.1 Hz),92.47(d, J-8.2 Hz),83.54(d, J-16.1 Hz),75.98(d, J-2.8 Hz),67.04,63.34,43.56,40.85,33.85(d, J-4.3 Hz),32.54, 31.18-29.48 (m), high resolution (d, J-18, J-23.23 Hz), theoretical high resolution (C-11.11 Hz), theoretical data (d, J-1 Hz), theoretical data (C, J-11.11 Hz), theoretical data (d, J-3 Hz), 3.3Hz), 32.54, 31.18-29.48, 27.18, J-18, J-3, 18, 3, h, and high resolution data (d, 3, h, 3,2, 3, h, 2,3, 2,3, 2,3, 2,3, 2,3, h, etc34H44NPIr+([M-BArF]+) 690.28351, experimental data 690.28350.
Example 26
Figure BDA0002426768050000303
(SC,RN) Synthesis of (E) -2f
Specific operation with reference to example 21, starting materials used were
Figure BDA0002426768050000311
The yield was 85%. Nuclear magnetic resonance (500MHz, Chloroform-d) δ 8.04-7.96 (m,2H), 7.79-7.72 (m,8H), 7.66-7.60 (m,1H), 7.58-7.46 (m,10H), 7.34-7.29 (m,1H), 7.24-7.16 (m,2H), 4.81-4.72 (m,1H),4.27(d, J ═ 2.2Hz,1H), 4.11-4.05 (m,1H), 4.02-3.94 (m,1H), 3.47-3.37 (m,2H),2.65(d, J ═ 6.0Hz,3H), 2.52-2.42 (m,1H), 2.29-2.13 (m,2H), 2.09-2.00 (m,1H), 1H, 89-6.84H, 13) δ 6.11. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.48-160.76 (m),139.78(d, J ═ 15.5Hz),136.53,135.23-134.47 (m),132.48(d, J ═ 9.7Hz),132.20(d, J ═ 2.7Hz),131.76,131.62(d, J ═ 2.3Hz),131.53(d, J ═ 2.3Hz),131.33,130.54(d, J ═ 6.6Hz), 129.50-128.41 (m),127.81,125.64,124.26,123.89,123.48,121.31,117.46(p, J ═ 4.0Hz),92.10(d, J ═ 8.1Hz),82.81(d, J ═ 16.1Hz),76.09(d, J ═ 2.6Hz),66.46,63.69, mass spectrum 43.35,43.14,33.66(d, J ═ 4.2), high resolution (32.44, 30.31.31, 31.31.31, 27.31.31 Hz), theoretical data (d, J ═ 8.6Hz), 66.46,63.69, 27.27.7 Hz), 3.31.7.7 Hz, 27.7, 3, 8, h, and so on35H46NPIr+([M-BArF]+) 704.29916, experimental data 704.29817.
Example 27
Figure BDA0002426768050000312
(SC,RN) Synthesis of-2 g
Reference method three, in a 50mL dry Schlenk reaction flask, add under helium atmosphere
Figure BDA0002426768050000313
(0.5mmol)、[Ir(COD)Cl]2(0.25mmol), NaBARF (661mg) and dry dichloromethane solvent (10mL) were stirred at 50 ℃ for 6h, TLC was sampled and heating was stopped when ligand was completely complexed and the system allowed to cool to room temperature naturally. Then separating the organic phase with Na2SO4Drying, spin-drying solvent, and purifying by column chromatography to obtain
Figure BDA0002426768050000321
The yield was 27%. Nuclear magnetic spectrum (400MHz, Chloroform-d) delta 8.03-7.93 (m,2H), 7.76-7.63 (m,9H), 7.60-7.49 (m,9H), 7.48-7.38 (m,3H), 7.34-7.28 (m,1H), 7.20-7.10 (m,2H),7.04(s,2H),5.51(s,1H),4.45(s,1H),4.29(s,1H),3.73(s,3H), 3.47-3.29 (m,2H), 2.84-2.74 (m,1H),2.49(d, J ═ 6.1Hz,3H), 2.39-2.27 (m,1H), 2.20-1.91 (m,2H), 1.75-1.32 MHz, 23H (cl), 23 MHz, 202 MHz), nuclear magnetic spectrum3) δ 11.51. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.53-160.68 (m),145.45,141.58(d, J ═ 15.8Hz),135.89,134.95(d, J ═ 12.2Hz),134.78,133.50(d, J ═ 10.3Hz), 132.99-132.32 (m),131.65(d, J ═ 2.5Hz), 130.43-128.22 (m),127.75(d, J ═ 11.7Hz),127.25,126.93,125.63,123.88-123.03 (m),121.29,117.68-35 117.33(m),93.05(d, J ═ 12.5Hz),92.72(d, J ═ 11.5Hz),72.79(d, J ═ 4.1Hz),65.70,64.36,63.25,43.49(d, J ═ 2.0Hz),36.10,32.99(d, J ═ 3.5Hz), 30.84, 29.7 Hz), theoretical high-resolution data (d, J ═ 2.7.7 Hz), theoretical data (d, J ═ 29.7.7 Hz), theoretical data (d, J ═ 2.06.7 Hz), theoretical data (d, J ═ 7.7.7 Hz), 3.7.7 Hz), 3.7Hz, 3.7, 3.5Hz, 3.7, 343H54NOPIr+([M-BArF]+) 824.35668, experimental data 824.35675.
Example 28
Figure BDA0002426768050000322
(SC,SN) Synthesis of (E) -2a
Reference method two, in a 50mL dry Schlenk reaction flask, add under helium atmosphere
Figure BDA0002426768050000323
(0.5mmol)、[Ir(COD)Cl]2(0.25mmol), NaBARF (661mg) and dry dichloromethane solvent (10mL) were stirred at 50 ℃ for 6 h. Then separating the organic phase with Na2SO4Drying, spin-drying solvent, and purifying by column chromatography to obtain
Figure BDA0002426768050000331
The yield was 74%. Hydrogen nuclear magnetic spectrum (500MHz, Chloroform-d) delta 8.00-7.92 (m,2H), 7.81-7.76 (m,9H), 7.75-7.71 (m,1H), 7.62-7.50(m,11H), 7.35-7.26 (m,3H), 5.02-4.95 (m,1H), 4.60-4.57 (m,1H), 4.33-4.27 (m,1H), 3.97-3.91 (m,1H), 3.47-3.42 (m,1H), 3.26-3.20 (m,1H), 2.50-2.38 (m,2H),2.36(d, J ═ 5.9Hz,3H), 2.29-2.20 (m,1H), 2.15-2.06 (m,1H), 2.05-1.89 (m,3H), 1.78-1.70 (m,1H),1.01(s,9H) phosphorus nuclear magnetic spectrum (202MHz, CDCl)3) δ 9.35. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.41-161.07 (m),136.90(d, J-11.4 Hz),135.45(d, J-11.8 Hz),134.82,133.38(d, J-10.9 Hz),133.06(d, J-3.7 Hz),132.68(d, J-2.4 Hz),132.05(d, J-2.4 Hz),131.33(d, J-2.2 Hz), 130.04-128.39 (m),128.00,127.83,125.66,124.60,124.16,123.50,121.33,117.64-117.36 (m),93.53(d, J-10.5 Hz),87.10(d, J-13.7 Hz),72.25(d, J-13.3 Hz),69.40,61.19,37.13,35.80,32.19(d, J-3.6), high resolution (d, J-13.55, J-3 Hz), theoretical high resolution (d, J-3.7.7 Hz), 15.8, 7.6, 7.7, 7.6, 7.7.8, 7.6, 7.7, 7.7.6, 7, 7.7, 7,3, 7,3, 7,3, 7,3, 7,3, 732H40NPIr+([M-BArF]+) 662.25221, experimental data 662.25231.
Example 29
Figure BDA0002426768050000332
(SC,SN) Synthesis of (E) -2b
Specific operation with reference to example 28, the starting material used was
Figure BDA0002426768050000333
The yield was 76%. Nuclear magnetic spectrum (500MHz, Chloroform-d) δ 7.98-7.91 (m,2H), 7.86-7.82 (m,1H), 7.76-7.71 (m,9H), 7.65-7.60 (m,1H), 7.59-7.47 (m,11H), 7.28-7.22 (m,2H), 5.03-4.97 (m,1H), 4.33-4.27 (m,2H), 4.13-4.07 (m,1H), 3.43-3.36 (m,1H), 3.20-3.13 (m,1H), 2.47-2.35 (m,2H),2.30(d, J ═ 5.8Hz,3H), 2.26-2.17 (m,1H), 2.12-1.84 (m,7H), 1.76-1H (m, 44H), phosphorus (m, 202 cl), nuclear magnetic spectrum CDCl, 1H), 2H, 2MHz, 2H, 2MHz, 2MHz, 2, 1H, 2, 1H, 2, m,2, 1,2, 1,2, c, 2, c, b, c, b, c, b, c, b, c, b, c, b, c, b, c, b, c3) δ 9.52. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 161.72(dd, J ═ 99.5,49.9Hz),136.56(d, J ═ 11.3Hz),135.50(d, J ═ 11.3Hz),134.81,133.68-127.47 (m),125.65,124.61,124.17,123.48,121.32,117.50,93.40(d, J ═ 10.3Hz),86.90(d, J ═ 13.4Hz),73.26(d, J ═ 14.1Hz),69.30,61.07,40.15,38.19,37.67,36.11,32.25(d, J ═ 3.6Hz),31.50,30.50,29.72,29.02,27.91. high resolutionTheoretical data of mass spectrum C38H46NPIr+([M-BArF]+) 740.29916, experimental data 740.29890.
Example 30
Figure BDA0002426768050000341
(SC,SN) Synthesis of (E) -2c
Specific operation with reference to example 28, the starting material used was
Figure BDA0002426768050000342
The yield was 83%. Nuclear magnetic spectrum (400MHz, Chloroform-d) δ 7.98(d, J ═ 11.4Hz,1H), 7.74-7.69 (m,11H), 7.54-7.42 (m,12H), 7.34-7.27 (m,1H), 7.24-7.18 (m,1H), 7.13-7.07 (m,1H),4.71(d, J ═ 8.6Hz,1H), 4.59-4.45 (m,2H), 3.64-3.46 (m,2H), 2.75-2.60 (m,1H), 2.40-1.79 (m,7H), 1.71-1.39 (m,5H), 1.32-1.08 (m,6H), 1.02-0.76 (m,3H), phosphorus nuclear magnetic spectrum (CDCl (202MHz, CDCl), 1H), etc3) δ 6.75 carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 163.21,162.59-160.82 (m),143.45(d, J ═ 14.5Hz),135.65,134.79,133.89(d, J ═ 12.0Hz),132.65(d, J ═ 10.4Hz),132.20(d, J ═ 2.4Hz), 132.05-131.68 (m), 130.80-127.36 (m),125.62,123.46,122.96,122.57,121.29,117.65-117.28 (m),97.54(d, J ═ 10.9Hz),90.94(d, J ═ 12.6Hz),87.33,69.26,67.39,47.11,32.90,32.29(d, J ═ 3.2Hz),31.47(d, J ═ 3.1Hz),31.15,29.99,29.81,25.93(d, J ═ 17.2Hz), high resolution theoretical C data (C51, 25.51 Hz), high resolution data34H42NPIr+([M-BArF]+) 688.26786, experimental data 688.26757.
Example 31
Figure BDA0002426768050000343
(SC,SN) Synthesis of-2 d
Specific operation with reference to example 28, the starting material used was
Figure BDA0002426768050000344
The yield was 81%. Hydrogen nuclear magnetic spectrum (400MHz, Chloroform-d) delta 7.97-7.88 (m,2H), 7.76-7.67 (m,10H), 7.58-7.48 (m,11H), 7.30-7.26 (m,1H), 7.23-7.16 (m,2H), 4.94-4.86(m,1H),4.63(s,1H), 4.27-4.16 (m,1H), 3.88-3.78 (m,1H), 3.43-3.35 (m,1H), 3.18-3.10 (m,1H), 2.48-2.32 (m,2H),2.31(d, J ═ 5.9Hz,3H), 2.24-2.13 (m,1H), 2.11-2.00 (m,1H), 2.00-1.87 (m,3H), 1.76-1.64 (m,1H), 1.47-1.15 (m,4H),1.11(s,3H), 1.06-0.91 (m,5H),0.66(t, J ═ 7.3Hz,3H) phosphorus spectra (202MHz, cl, 3 MHz), 3.18(m,1H) and 3H)3) δ 9.01. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.68-160.60 (m),136.87(d, J ═ 11.3Hz),135.70(d, J ═ 11.6Hz),134.81,133.26(d, J ═ 11.6Hz),132.77,132.04,131.37,130.38-127.06 (m),125.64,124.88,124.43,123.47,121.30,117.46,93.60(d, J ═ 10.5Hz),87.13(d, J ═ 13.5Hz),69.95,69.48,60.99,41.86,38.34,37.34,32.13,31.67,30.67,28.88,26.89,24.69(d, J ═ 22.3Hz),23.02,13.80. high resolution mass spectrometry theory data C, 31.67,30.67,28.88,26.89,24.69(d, J ═ 22.3Hz)35H46NPIr+([M-BArF]+) 704.29916, experimental data 704.29997.
Example 32
Figure BDA0002426768050000351
(SC,SN) Synthesis of-2 e
Specific operation with reference to example 28, the starting material used was
Figure BDA0002426768050000352
The yield was 86%. Hydrogen spectrum nuclear magnetism (500MHz, Chloroform-d) delta 8.01-7.93 (m,2H), 7.79-7.72 (m,9H), 7.60-7.50 (m,12H), 7.34-7.29 (m,1H), 7.26-7.20 (m,2H), 4.99-4.91 (m,1H),4.68(s,1H), 4.29-4.20 (m,1H), 3.95-3.88 (m,1H), 3.46-3.38 (m,1H), 3.20-3.10 (m,1H), 2.50-2.31 (m,4H), 2.28-2.16 (m,1H), 2.14-2.03 (m,1H), 2.03-1.89 (m,3H), 1.79-1.68 (m,1H),1.64 (m,1H), 1H, 0.63-0.31H), 1H, 3.31(m,1H), 3.31-2.31 (m,1H), 3.3.3.31-2.18H), 1H, 3.3.3.3.3.3.1H, 3.3.1H, 3.1H, 3, 3.1H, 3H, 3H, 3H, 3, 0.1H, 3H, 3, 1H, 3,1, 0.1, 3,1, 3, 1H, 3, 1H, 3, 0,3, 1,3, 1, 0,1, 3, 0,3, 1,3, 1,2, 3,2, 0,3, 2,3, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 3,2, 1,2, 1,2, 1,2, 3,2, 1,2, 1,2, 1,2, 1,2, 1,23) δ 8.83. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 161.70(dd, J ═ 99.7,49.9Hz),136.87(d, J ═ 11.2Hz),135.80(d, J ═ 11.8Hz),134.81,133.31,133.22,132.75(d, J ═ 2.4Hz),132.01(d, J ═ 2.5Hz),131.35,130.22-128.30 (m),127.76(d, J ═ 12.5Hz),127.28,125.64,125.09,124.65,123.47,121.31,117.79-117.16 (m),93.73(d, J ═ 10.4Hz),87.23(d, J ═ 13.6Hz),69.92,69.36(d, J ═ 13.1Hz),60.95,41.25,37.44,32.07(d, J is 3.6Hz),31.68(d, J is 2.8Hz),30.67,30.36,28.86(d, J is 2.6Hz),27.72,21.54,7.02,6.54. high resolution mass spectrometry theoretical data C34H44NPIr+([M-BArF]+) 690.28351, experimental data 690.28412.
Example 33
Figure BDA0002426768050000361
(SC,SN) Synthesis of (E) -2f
Specific operation with reference to example 28, the starting material used was
Figure BDA0002426768050000362
The yield was 88%. Hydrogen spectrum nuclear magnetism (500MHz, Chloroform-d) delta 8.02-7.94 (m,2H), 7.84-7.80 (m,1H), 7.79-7.72 (m,9H), 7.63-7.45 (m,9H), 7.36-7.31 (m,1H), 7.27-7.18 (m,2H), 4.99-4.92 (m,1H),4.78(s,1H), 4.30-4.21 (m,1H), 4.00-3.91 (m,1H), 3.48-3.38 (m,1H), 3.14-3.07 (m,1H), 2.54-2.33 (m,5H), 2.29-2.17 (m,1H), 2.13-1.91 (m,4H), 1.79-1.65 (m,4H),1.59 (m,1H), 1H, 0.71-1H, 9H), 1H, 9-1H, 9H, 1H, III, 1H, P3) δ 8.44. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.60-160.69 (m),137.21(d, J ═ 11.2Hz),136.02(d, J ═ 11.9Hz),134.81,133.43(d, J ═ 3.6Hz),133.20(d, J ═ 10.8Hz),132.75(d, J ═ 2.6Hz),131.97(d, J ═ 2.3Hz),131.37(d, J ═ 1.9Hz),129.97(d, J ═ 7.7Hz),129.68(d, J ═ 10.4Hz),129.54,129.36-128.40 (m),127.81,127.43,127.00,125.64,125.35,124.90,123.48,121.31,117.77-116.90 (m),93.78(d, J ═ 10.7Hz), 48(d, J ═ mass spectrum 3913.3 Hz),69.91,69.34(d, J ═ 13.2, 60, 17.53 (d, J ═ 8.7 Hz),23, 17.7, 17, 17.7 (d, J ═ 8.3.3 Hz),27.7, 7, 17.7, 7, 17,7, 23, 17,7, 8, Hz, 8, Hz, 8, Hz, 8, Hz, 8, 18, 8, Hz, 8, Hz, 18, 8, Hz, 18, Hz, 18, Hz, 18, Hz, 18, Hz, 18, Hz, 18, Hz, 18, Hz, 18, Hz, C, Hz, 18, Hz, C, Hz, C, Hz, C, Hz, C, Hz, C, Hz, C35H46NPIr+([M-BArF]+) 704.29916, experimental data 704.29920.
Example 34
Figure BDA0002426768050000363
(SC,SN) Synthesis of (E) -2g
In example 27 while simultaneously producing(SC,SN) -2 g' with a yield of 54%. Nuclear magnetic spectrum (400MHz, Chloroform-d) δ 8.09-8.02 (m,1H), 7.81-7.73 (m,2H),7.70(p, J ═ 2.1Hz,9H), 7.58-7.38 (m,12H), 7.25-7.11 (m,4H),7.06(s,2H),6.12(s,1H),4.32(d, J ═ 5.5Hz,1H),3.76(s,3H), 3.64-3.51 (m,2H), 3.15-3.06 (m,1H), 2.42-2.29 (m,1H), 2.23-2.06 (m,1H), 1.89-1.79 (m,1H), 1.78-1.62 (m,1H), 1.57-1.21H, 23-1.202 MHz, 1H), phosphorus (cl, 202 MHz), CDCl, 202H), nuclear magnetic spectrum3) δ 16.35. carbon spectrum nuclear magnetic (126MHz, Chloroform-d) δ 162.38-161.00 (m),160.85,159.81,145.31,143.76(d, J ═ 14.3Hz),135.05(d, J ═ 2.2Hz),134.79,134.19(d, J ═ 12.0Hz),132.60(d, J ═ 2.3Hz),132.41(d, J ═ 2.6Hz),132.30(d, J ═ 10.5Hz),131.91(d, J ═ 2.4Hz),131.84,130.73(d, J ═ 10.0Hz), 129.94-129.60 (m), 129.35-128.40 (m),128.28,127.89,127.79,126.05,125.61(d, J ═ 3.2Hz),124.25,123.86,123.45,121.29,117.70-117.21 (m),97.80(d, J ═ 11.8Hz),92.47(d, J ═ 12.0Hz),83.37(d, J ═ 3.8, J ═ 3.85, J ═ 3.6, 19, 19.85, 19, 7.6, 3.6, 19(d, J ═ 3.6, h), theoretical 16.6, 3.6, h), theoretical d, J ═ 3.6, h, 3.6, h, theoretical d, h, 3.6, h, theoretical data (d, h), 3.6.6.6 Hz), 3.6Hz), theoretical data (d, h, 18, h, 3.6, 18h, 3.6h, 18h, 18h, etc., 3, etc., 18h, etc., 18h, etc., 3, etc., 18h, etc., 3, etc., 18h, etc., 3, 18h, etc., 18h, etc., 3, 18h, etc., 3, 18, etc., 3, 18h43H54NOPIr+([M-BArF]+) 824.35668, experimental data 824.35682.
EXAMPLE 35 asymmetric catalytic hydrogenation of five-membered Ring unsaturated carbonyl Compound
The Rong-Phos iridium complex obtained in example 21 was added
Figure BDA0002426768050000371
(SC,RN) -2a for the catalysis of the reaction, operating in particular as: weighing Rong-Phos iridium complex
Figure BDA0002426768050000372
(SC,RN) -2a (2.4mg) and Compound
Figure BDA0002426768050000373
(0.15mmol) was placed in a 10mL hydrogenation reaction tube equipped with a stirrer, vacuum-pumped, nitrogen-exchanged, toluene (1.5mL) was added under nitrogen atmosphere, and cooling with liquid nitrogen-vacuum-pumped, and this was repeated three times. Transferring the reaction tube into an autoclave, filling hydrogen (50atm) for reaction. After 12 hours the autoclave was opened and the product was analyzed by column chromatography for yield and by HPLC for enantiomeric excess (ee).
The specific catalytic reaction is shown as the following reaction formula:
Figure BDA0002426768050000381
column chromatography analysis revealed that: yield of target product 95%: HPLC analysis gave: ee ═ 66%
Of the target product1H NMR(500MHz,Chloroform-d)δ7.36–7.27(m,5H),7.26–7.19(m,5H),4.48(q,J=15.0Hz,2H),3.28(dd,J=13.2,3.6Hz,1H),3.13(dt,J=9.8,7.7Hz,1H),3.04(td,J=9.2,3.5Hz,1H),2.86–2.71(m,2H),2.09–1.97(m,1H),1.77–1.67(m,1H);13C NMR (126MHz, Chloroform-d) delta 175.80,139.38,136.51,129.12,128.66,128.45,128.10,127.52,126.32,46.79,44.78,43.66,37.03, 24.01. High resolution mass spectrometry theoretical data C18H19NNaO+288.1359, Experimental data 288.1359. Chirality was determined by HPLC using an ADH chiral column (hexane: 2-propanol ═ 90:10,1.0mL/min,210 nm); the retention time for the large enantiomer was 10.7min and for the small enantiomer 11.8 min. [ alpha ] to]D 22=+55.48(c=1.0,CHCl3)。
Examples 36 to 47
Investigation of the Rong-Phos Iridium Complex according to the invention, Compound 2, ligand R2The effect of the substituents, hydrogen pressure and solvent on the reaction, the specific operation and the rest of the conditions are described in example 35. The reaction conditions and experimental results of the examples are shown in Table 1.
TABLE 1 reaction conditions and results of examples 36-47
Figure BDA0002426768050000382
Figure BDA0002426768050000391
(S) is illustrated by examples 36 to 47C,RN) -2b and (S)C,SN) -2 b' is the most suitable catalyst for the preparation of S and R configurations, notably Rong-Phos iridium complex (S)C,RN) -2b gave the S-configuration target in 96% yield, 90% ee, and Rong-Phos iridium complex (S)C,SN) The-2 b' gives the R-configuration target in 96% yield in 98% ee, a chiral inversion occurs, and the two iridium complexes (S)C,RN) -2b and (S)C,SN) The-2 b' is prepared from the same ligand Rong-Phos (S) -1b, the two differences are only in chirality on the two nitrogen atoms, and the control of the chirality of the nitrogen atoms realizes that the target products of two configurations can be obtained by using the same ligand with excellent enantioselectivity and excellent yield, which is very challenging.
Examples 48 to 71
Examining the general applicability of the substrates described in the present invention, the (S) pairsC,RN) -2b and (S)C,SN) 2 b' two iridium complexes were investigated, and the specific procedures and the remaining conditions were as described in example 43. The reaction conditions and experimental results of the examples are shown in Table 2.
The catalytic reaction is shown in the following formula (5):
Figure BDA0002426768050000401
TABLE 2 reaction conditions and results of examples 48-71
Figure BDA0002426768050000402
Figure BDA0002426768050000411
By way of examples 48 to 71, in the case of five-membered ring cyclic unsaturated carbonyl compoundsIn the application of symmetric catalytic hydrogenation reaction, the iridium complex (S)C,RN) 2b has better substrate universality, and the iridium complex (S)C,SN) The-2 b' shows excellent enantioselectivity on the basis of good universality, and has high reaction activity and enantioselectivity.
EXAMPLE 72 asymmetric catalytic hydrogenation of six-membered cyclic unsaturated carbonyl Compounds
The Rong-Phos iridium complex obtained in example 27 was added
Figure BDA0002426768050000412
(SC,RN) 2g of catalyst for the reaction, operating in particular: weighing Rong-Phos iridium complex
Figure BDA0002426768050000413
(SC,RN) -2g (2.5mg) and Compound
Figure BDA0002426768050000421
(0.15mmol) was placed in a 10mL hydrogenation reaction tube equipped with a stirrer, vacuum was applied, nitrogen was exchanged, methylene chloride (1.5mL) was added under nitrogen, and cooling with liquid nitrogen-vacuum application was repeated three times. The reaction tube was transferred to an autoclave and charged with hydrogen (20atm) for reaction. After 12 hours the autoclave was opened and the product was analyzed by column chromatography for yield and by HPLC for enantiomeric excess (ee).
The specific catalytic reaction is shown as the following reaction formula:
Figure BDA0002426768050000422
column chromatography analysis revealed that: yield of the target product 71%: HPLC analysis gave: ee is 75%
Of the target product1H NMR(400MHz,Chloroform-d)δ7.32–7.12(m,5H),3.76–3.65(m,1H),3.62–3.51(m,1H),3.45–3.34(m,1H),2.69–2.57(m,2H),1.91–1.63(m,3H),1.54(s,9H);13C NMR(101MHz,Chloroform-d)δ173.61,152.96,139.60,129.22,128.38,126.24,82.76,45.75,45.58,37.09,28.05,25.34,21.57. High resolution mass spectrometry theoretical data C17H23NNaO3 +312.1570, Experimental data 312.1571. Chirality was determined by HPLC using an OZ-3 chiral column (hexane: 2-propanol ═ 95:5,0.5mL/min,210 nm); the large enantiomer retention time was 17.3min and the small enantiomer retention time was 21.3 min. [ alpha ] to]D 22=+82.33(c=1.0,CHCl3)。
Examples 73 to 77
The specific operation and the rest conditions were examined for the effect of the Rong-Phos iridium complex of the present invention, i.e., Compound 2, on the reaction under the hydrogen pressure and the solvent, and were described in example 72. The reaction conditions and experimental results of the examples are shown in Table 3.
TABLE 3 reaction conditions and results of examples 73-77
Figure BDA0002426768050000423
Figure BDA0002426768050000431
(S) is illustrated by examples 73 to 74C,SN) 2 g' is the most suitable catalyst, indicating a hydrogen pressure of 30atm as the most suitable pressure by examples 74 to 75 and DCE as the most suitable solvent by examples 75 to 77, giving the desired product of the R configuration in 99% yield with 96% ee.
Examples 78 to 87
Examination of the general applicability of the substrates described in the present invention, to (S)C,SN) 2 g' were examined, and the specific operations and the remaining conditions were as described in example 77. The reaction conditions and experimental results of the examples are shown in Table 4.
The catalytic reaction is shown in the following formula (6):
Figure BDA0002426768050000432
TABLE 4 reaction conditions and results of examples 78-87
Figure BDA0002426768050000433
Figure BDA0002426768050000441
By way of examples 78 to 87, the iridium complex (S) is used in the asymmetric catalytic hydrogenation of six-membered ring cyclic unsaturated carbonyl compoundsC,SN) 2 g' has excellent substrate universality and very high reaction activity and enantioselectivity.
EXAMPLE 88 asymmetric catalytic hydrogenation of seven-membered cyclic unsaturated carbonyl Compounds
The Rong-Phos iridium complex obtained in example 27 was added
Figure BDA0002426768050000451
(SC,RN) 2g of catalyst for the reaction, operating in particular: weighing Rong-Phos iridium complex
Figure BDA0002426768050000452
(SC,RN) -2g (2.5mg) and Compound
Figure BDA0002426768050000453
(0.15mmol) was placed in a 10mL hydrogenation reaction tube equipped with a stirrer, vacuum was applied, nitrogen was exchanged, methylene chloride (1.5mL) was added under nitrogen, and cooling with liquid nitrogen-vacuum application was repeated three times. The reaction tube was transferred to an autoclave and charged with hydrogen (30atm) for reaction. After 12 hours the autoclave was opened and the product was analyzed by column chromatography for yield and by HPLC for enantiomeric excess (ee).
The specific catalytic reaction is shown as the following reaction formula:
Figure BDA0002426768050000454
column chromatography analysis revealed that: yield of target product 98%: HPLC analysis gave: ee is 60%
Of the target product1H NMR(400MHz,Chloroform-d)δ7.32–7.23(m,2H),7.22–7.16(m,3H),4.27–4.17(m,1H),3.35(dd,J=15.3,10.6Hz,1H),3.26(dd,J=14.1,5.3Hz,1H),2.96–2.85(m,1H),2.58(dd,J=14.1,8.7Hz,1H),1.91–1.71(m,3H),1.52(s,9H),1.49–1.38(m,3H);13C NMR (101MHz, Chloroform-d) delta 176.76,153.32,140.12,129.31,128.33,126.11,82.71,47.87,45.29,38.11,29.34,28.43, 28.05. High resolution mass spectrometry theoretical data C18H25NNaO3 +326.1726, Experimental data 326.1722. Chirality was determined by HPLC using an AS-H chiral column (hexane: 2-propanol ═ 98:2,1.0mL/min,210 nm); the retention time for the small enantiomer was 5.0min and for the large enantiomer 5.8 min. [ alpha ] to]D 22=-9.27(c=1.0,CHCl3)。
Examples 89 to 90
The specific operation and the rest conditions were as described in example 88, considering the effect of the Rong-Phos iridium complex of the present invention, i.e., Compound 2, on the reaction. The reaction conditions and experimental results of the examples are shown in Table 5.
TABLE 5 reaction conditions and results of examples 89-90
Figure BDA0002426768050000461
(S) is illustrated by examples 96 to 97C,SN) 2 g' of the most suitable catalyst gave the desired product in the R configuration in 99% yield, 96% ee.
Examples 91 to 98
Examination of the general applicability of the substrates described in the present invention, to (S)C,SN) 2 g' were examined, and the specific operations and the remaining conditions were as described in example 90. The reaction conditions and experimental results of the examples are shown in Table 6.
The catalytic reaction is shown in the following formula (7):
Figure BDA0002426768050000462
TABLE 6 reaction conditions and results of examples 91-98
Figure BDA0002426768050000471
By way of examples 91 to 98, the iridium complex (S) is used in the asymmetric catalytic hydrogenation of a seven-membered ring, cyclic, unsaturated carbonyl compoundC,SN) 2 g' has excellent substrate universality and very high reaction activity and enantioselectivity.
The protection of the present invention is not limited to the above embodiments. Variations and advantages that may occur to those skilled in the art may be incorporated into the invention without departing from the spirit and scope of the inventive concept, and the scope of the appended claims is intended to be protected.

Claims (11)

1. A chiral bidentate nitrogen phosphine ligand Rong-Phos, which is characterized in that the chiral bidentate nitrogen phosphine ligand is a compound shown as the following formula (1) or an enantiomer or a racemate:
Figure FDA0003270182330000011
in the formula:
ar is selected from
Figure FDA0003270182330000012
R1Is selected from
Figure FDA0003270182330000013
R2Is selected from C1~C12An alkyl group of,
Figure FDA0003270182330000014
R3Selected from hydrogen;
R4and R5Is C1~C12An alkyl group and hydrogen,
Figure FDA0003270182330000015
And hydrogen;
wherein R isxAnd Rx’Are each independently selected from C1~C12Alkyl of (A), C1~C10Alkoxy group of (a);
n is an integer of 1 to 5.
2. The chiral bidentate phosphine nitride Rong-Phos is characterized in that the chiral bidentate phosphine nitride Rong-Phos is an optically pure compound with the structure shown as formula (S) -1 and (R) -1;
Figure FDA0003270182330000016
in the formula:
ar is selected from
Figure FDA0003270182330000017
R1Is selected from
Figure FDA0003270182330000021
R2Selected from hydrogen, C1~C12An alkyl group of,
Figure FDA0003270182330000022
R3Selected from hydrogen;
R4and R5Is C1~C12An alkyl group and hydrogen,
Figure FDA0003270182330000023
And hydrogen;
wherein R isxAnd Rx’Are each independently selected from C1~C12Alkyl of (A), C1~C10Alkoxy group of (a);
n is an integer of 1 to 5.
3. The chiral bidentate phosphine nitride-Phos according to claim 1 or 2, characterized in that,
wherein the content of the first and second substances,
ar is selected from benzene ring;
R1is selected from phenyl;
R2selected from the group consisting of tert-butyl, adamantyl, cyclohexyl, - (CH)3)2 nBu、-(CH2CH3)2Me、-(CH2CH3)34-methoxy-3, 5-di-tert-butylphenyl; r3Selected from hydrogen;
R4and R5Methyl and hydrogen, n-butyl and hydrogen, benzyl and hydrogen.
4. The chiral bidentate phosphine nitride-Phos according to claim 1, having the structure:
Figure FDA0003270182330000024
5. the preparation method of the chiral bidentate phosphine nitride ligand Rong-Phos as claimed in claim 2, which comprises the following steps:
the method comprises the following steps:
the first step is as follows: starting from a compound of the following formula (3), under the action of a base, and reacting with R4Carrying out substitution reaction on the X to obtain a nitrogen atom substituted Ming-Phos compound;
Figure FDA0003270182330000031
R6independently selected from tert-butyl;
wherein the compound of formula (3) comprises formula (S)C,RS) -3, formula (S)C,SS) -3, formula (R)C,SS) -3, formula (R)C,RS)-3;
Wherein the nitrogen atom substituted Ming-Phos compound comprises the formula (S)C,RS) -4, formula (S)C,SS) -4, formula (R)C,SS) -4, formula (R)C,RS)-4;
Wherein the base comprises BuLi, NaH, K2CO3,Na2CO3,KHCO3,NaHCO3,KOH,NaOH;
The reaction scheme of the first step is as follows:
Figure FDA0003270182330000032
the second step is that: the compound of formula (S)C,RS) -4, formula (S)C,SS) -4, formula (R)C,SS) -4, formula (R)C,RS) -4, under the action of hydrochloric acid, carrying out hydrolysis reaction to obtain chiral bidentate phosphine nitride Rong-Phos formula (S) -1 and formula (R) -1;
wherein the reaction formula of the second step is as follows:
Figure FDA0003270182330000041
wherein each group is as defined in claim 2.
6. The method according to claim 5,
the temperature of the first step reaction is-78-30 ℃;
the reaction time of the first step is 0.5 to 12 hours;
the temperature of the second step reaction is 0-30 ℃;
the time of the second step reaction is 0.5 to 12 hours.
7. The process for the preparation of chiral bidentate phosphine nitride ligand Rong-Phos according to claim 2, which comprises the following steps:
the second method comprises the following steps:
the first step is as follows: starting from a compound shown as the following formula (3), carrying out hydrolysis reaction under the action of hydrochloric acid to obtain intermediates shown as formula (A) and formula (B): wherein the compound of formula (3) comprises formula (S)C,RS) -3, formula (S)C,SS) -3, formula (R)C,SS) -3, formula (R)C,RS)-3;
Figure FDA0003270182330000051
Wherein the reaction formula of the first step is as follows:
Figure FDA0003270182330000052
the second step is that: the intermediates shown in the formula (A) and the formula (B) are subjected to condensation with aldehyde and reduction by a reducing agent to obtain chiral bidentate phosphine nitride Rong-Phos formula (S) -1 and formula (R) -1;
wherein the reaction formula of the second step is as follows:
Figure FDA0003270182330000061
wherein each group is as defined in claim 2;
R6independently selected from tertiary butyl.
8. The process for preparing a chiral bidentate phosphine nitride ligand Rong-Phos as claimed in claim 7,
the temperature of the first step reaction is 0-30 ℃;
the reaction time of the first step is 0.5 to 12 hours;
the temperature of the second step reaction is 0-30 ℃;
the time of the second step reaction is 0.5 to 12 hours.
9. The process for the preparation of chiral bidentate phosphine nitride ligand Rong-Phos according to claim 2, which comprises the following steps:
the third method comprises the following steps:
the first step is as follows: starting from a compound shown in the following formula (3), carrying out hydrolysis reaction under the action of hydrochloric acid to obtain an intermediate shown in the formula (A) and the formula (B); wherein the compound of formula (3) comprises formula (S)C,RS) -3, formula (S)C,SS) -3, formula (R)C,SS) -3, formula (R)C,RS)-3;
Figure FDA0003270182330000062
Wherein the reaction formula of the first step is as follows:
Figure FDA0003270182330000071
the second step is that: reacting an intermediate shown in a formula (A) and a formula (B) with R under the action of alkali4X and R5X is subjected to substitution reaction to obtain chiral bidentate nitrogen phosphine ligand Rong-Phos formula (S) -1 and formula (R) -1;
wherein the reaction formula of the second step is as follows:
Figure FDA0003270182330000072
wherein each group is as defined in claim 2;
R6independently selected from tertiary butyl.
10. The method according to claim 9,
the temperature of the first step reaction is 0-30 ℃;
the reaction time of the first step is 0.5 to 12 hours;
the temperature of the second step reaction is 0-100 ℃;
the time of the second step reaction is 1-24 hours.
11. Use of the chiral bidentate phosphine nitride ligand Rong-Phos according to claim 1 or 2 for the preparation of iridium complexes of Rong-Phos and for asymmetric catalytic hydrogenation.
CN202010223130.7A 2020-03-26 2020-03-26 Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof Active CN111393476B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010223130.7A CN111393476B (en) 2020-03-26 2020-03-26 Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010223130.7A CN111393476B (en) 2020-03-26 2020-03-26 Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN111393476A CN111393476A (en) 2020-07-10
CN111393476B true CN111393476B (en) 2021-11-19

Family

ID=71427657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010223130.7A Active CN111393476B (en) 2020-03-26 2020-03-26 Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN111393476B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745049A (en) * 2002-12-09 2006-03-08 麻省理工学院 Ligands for metals and improved metal-catalyzed processes based thereon
CN106632478A (en) * 2016-12-01 2017-05-10 武汉凯特立斯科技有限公司 Chiral bidentate nitrogen-containing phosphine ligands and application thereof in asymmetric catalytic reaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745049A (en) * 2002-12-09 2006-03-08 麻省理工学院 Ligands for metals and improved metal-catalyzed processes based thereon
CN106632478A (en) * 2016-12-01 2017-05-10 武汉凯特立斯科技有限公司 Chiral bidentate nitrogen-containing phosphine ligands and application thereof in asymmetric catalytic reaction

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A New Phosphine-Amine-Oxazoline Ligand for Ru-Catalyzed Asymmetric Hydrogenation of N-Phosphinylimines;Ma, X. et al.;《 Z. Chin. J. Chem.》;20181008;第36卷;1151-1155 *
Chiral phosphine ligands in asymmetric synthesis. IV. Hydrosilation of ketones, and the structure of (bicyclo[2.2.l]hepta-2,s-diene)[N,N-dimethyl-1(R)-(o-(bis(tert-butyl)phosphino) phenyl)ethylamine]rhodium(I) perchlorate;IAN D. MCKA et al.;《Can. J. Chem.》;19861231;第64卷;1930-1935 *
L. Horner et al..Studien zum Vorgang der Wasserstoffübertragung,72[1]Versuche zur enantioselektiven Homogenhydrierung von N-Acyl-a-aminozimtsäuren mit Rh(I)-KompIexen unter Verwendung neuer optisch aktiver Co-Katalysatoren.《Z. Naturforsch.》.1984,第39b卷 *
Neue optisch aktive Chelat-Phosphane - Synthese und Verwendung in der enantioselektiven Katalyse;H. Brunne et al.;《Chcm. Ber.》;19901231;第123卷;847-853 *
Nitrogen- and phosphorus-coordinated nickel(II) complexes as catalysts for the oligomerization of ethylene;M.E. Bluhm et al.;《Journal of Molecular Catalysis A: Chemical》;20050104;第229卷;177-181 *
Novel P,N Ligands Derived from (R)- and (S)-1-Phenylethylamine with (2R,5R)-2,5-Dimethylphospholanyl Groups (DuPHAMIN) for Asymmetric Catalysis;David J. Brauer et al.;《Eur. J. Inorg. Chem.》;20031231;1748-1755 *
PHOSPHORORGANISCHE VERBINDUNGEN 107" DIE SYNTHESE ZWEIFACH CHIRALER TERTURER MOGLICHE CHELATLIGANDEN FUR HOMOGENKATALY SEN PHOSPHINE UND VON BIS-N,P-CHELATEN ALS MOGLICHE CHELATLIGANDEN FUR HOMOGENKATALYSEN;L. HORNER et al.;《Phosphorus and Sulfur》;19841231;第19卷;65-75 *

Also Published As

Publication number Publication date
CN111393476A (en) 2020-07-10

Similar Documents

Publication Publication Date Title
JP3497165B2 (en) Chiral catalyst, catalytic oxidation and disproportionation reaction, and method for producing epoxy chroman and taxol
KR19980702982A (en) Stereoselective ring opening reaction
CN109718851B (en) Chiral quaternary phosphonium salt phase transfer catalyst and preparation method and application thereof
CN107698590A (en) A kind of method of asymmetry [3+2] cyclization five yuan of carbocyclic purine nucleosides of synthesis of chiral
CN104478919A (en) Method for synthesizing chiral silane compound
Catasús et al. β-Ferrocenyl-β-amino alcohols: a new class of central chiral ferrocene derivatives
CN111925356B (en) Synthesis method and application of chiral quinoline-imidazoline ligand
JP2014040457A (en) Method of manufacturing phosphoroamide compound and optically active alcohol
CN111393476B (en) Chiral bidentate nitrogen phosphine ligand Rong-Phos and preparation method and application thereof
CN111499666B (en) Chiral bidentate nitrogen phosphine ligand Rong-Phos iridium complex and high-enantioselectivity construction and application of nitrogen chiral center thereof
CN109503670B (en) Chiral monophosphine ligand WJ-Phos of ferrocene skeleton, preparation method and application
JP4649645B2 (en) Process for producing optically active alcohol compounds
CN112110933A (en) Lignans natural product and intermediate and preparation method thereof
WO2009043303A1 (en) A method of stereoselectivity in the pd-catalyzed allylic substitution reaction
JP4474861B2 (en) Optically active quaternary ammonium salt, process for producing the same, and process for producing optically active α-amino acid derivative using the same
CN106146543A (en) Transition metal complex, three grades of borates of chirality alpha-amido and preparation method thereof
CN109503660B (en) Chiral monophosphine catalyst Le-Phos with cyclic phosphine skeleton and preparation method and application of full configuration thereof
JP3976357B2 (en) Method for producing optically active alcohol
CN1098856C (en) amidophosphinephosphinite compounds
Oh et al. Synthesis of Optically Pure 2, 2′‐Dimercurio‐1, 1′‐binaphthyl Compounds: Catalysis of Diels− Alder Reactions of O‐Ethyl Crotonthioate
CN109251227A (en) Chipal compounds of the one kind comprising ferrocene frame having ferrocene frame and rigid spirane structure and synthesis and application
CN108484451A (en) A kind of method that one kettle way prepares 1,2- alkamine compounds
CN112574164B (en) Method for synthesizing chiral spiro molecule based on chiral binaphthol
CN115340446B (en) Chiral benzocyclobutene alcohol, synthesis method and application thereof
JP6286755B2 (en) Novel diamine compound and metal complex, and method for producing optically active compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230908

Address after: Building C2-01, National Health Big Data Industrial Park, intersection of Xiyou Road and Kongquetai Road, High-tech Zone, Hefei City, Anhui Province, 230000

Patentee after: Anhui Kaitailai Platinum Technology Co.,Ltd.

Address before: 200241 No. 500, Dongchuan Road, Shanghai, Minhang District

Patentee before: EAST CHINA NORMAL University

TR01 Transfer of patent right